Systematic reviews and meta-analysis
Lead Research Organisation:
MRC Clinical Trials Unit
Abstract
A number of clinical trials comparing the same treatments might not show which treatment is best. In this situation, the CTU Meta-analysis Group searches for all the trials and describes them - a systematic review. Then, we put the results of these trials together in a meta-analysis. This gives a better picture of how good or bad a treatment is, than any single trial.|Most researchers use information written about trials for systematic reviews and meta-analyses. If trials are not written about or not written about in much detail, this method is not so reliable. Instead, we ask all the doctors who did the trials, for all the relevant information on each patient. This so called individual patient data method is much more reliable, but can take much longer. We are one of only a few groups worldwide that do systematic reviews and meta-analyses in this way.|In the past we have looked at treatments in ovarian, lung, oesophageal, bladder, brain, cervical and endometrial cancer, and sarcoma, as well as in pregnancy, human prion disease and venous leg ulcers. Now we have projects in lung and colorectal cancer, and in stroke.|We also research different ways of doing systematic reviews and meta-analyses, to try to improve how they are done.
Technical Summary
The Meta-analysis Group of the MRC Clinical Trials Unit (CTU) aims to rigorously evaluate the effectiveness of interventions for cancer and other diseases/conditions using systematic reviews and meta-analysis, to inform both clinical practice and research. We also aim to improve the quality and reliability of systematic reviews and meta-analyses through associated methodological research.|Moderate improvements in outcome are often the best that can be expected of new interventions, but these can be clinically worthwhile and important in terms of public health. Where randomised trials recruit too few patients to detect such modest differences reliably, they may have inconclusive results, or by chance, have results in favour of a particular intervention. Collating and appraising such trials in a systematic review, provides an objective summary of all the available evidence. Combining the results of these trials in a meta-analysis, can give sufficient statistical power to obtain a reliable and precise estimate of effect.|The Group predominantly conducts systematic reviews and meta-analyses based on individual patient data (IPD MA). These involve the collection, checking and re-analysis of the original IPD from all the relevant trials worldwide, necessitating extensive collaboration. Compared to standard systematic reviews based on trial-level data extracted from publications or obtained from trial investigators, the collection of IPD can improve the quality of data and breadth of analysis, and so it is considered the gold standard approach. As IPD MAs are resource-intensive and take time to complete, we also use standard systematic reviews to identify questions that require the IPD approach, when a more timely answer is needed, or when resource is limited. We are one of few groups worldwide with expertise in IPD MAs and have an international reputation in their conduct.|The Group has completed IPD MAs and other systematic reviews of therapies for ovarian, lung, oesophageal, bladder, brain and cervical cancer, and soft tissue sarcoma, as well as human prion disease, pre-eclampsia and venous leg ulcers. We have ongoing projects in lung and colorectal cancer, and in stroke. We are piloting consumer involvement in our IPD projects. Methodological projects have included investigations of publication and patient exclusion bias, and the development of methods for analysing published time-to-event data. Ongoing projects include comparing meta-analyses based on summary data with those based on IPD, evaluating the methods for assessing treatment by patient covariate interactions and methods for analysing IPD.|We act as the main CTU link to the Cochrane Collaboration, with members of the Group active in a number of Cochrane Review Groups and Methods Groups. We also co-convene the IPD Meta-analysis Methods Group.
Organisations
- MRC Clinical Trials Unit (Lead Research Organisation)
- Shanghai University of Traditional Chinese Medicine (Collaboration)
- University of Yamanashi (Collaboration)
- Circolo Hospital and Macchi Foundation (Collaboration)
- University of Edinburgh, United Kingdom (Collaboration)
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (TCM) (Collaboration)
- Mayo Clinic (Collaboration)
- Newcastle General Hospital (Collaboration)
- University College London Hospital (Collaboration)
- Radiation Therapy Oncology Group RTOG (Collaboration)
- Intermountain Medical Centre (Collaboration)
- University of Sydney, Australia (Collaboration)
- Acylbadem Oncology and Neurological Science Hospital (Collaboration)
- American College of Radiology (ACR) (Collaboration)
- University of California Los Angeles, United States (Collaboration)
- Osaka Medical Center for Cancer and Cardiovascular Diseases (Collaboration)
- International Academy of Environmental Sciences (IAES) (Collaboration)
- Uppsala University Hospital (Collaboration)
- SG Moscati Hospital (Collaboration)
- University of Rome I (La Sapienza), Italy (Collaboration)
- University of Paris South 11, France (Collaboration)
- University of Turin (Collaboration)
- Tom Baker Cancer Center (Collaboration)
- Saarland University, Germany (Collaboration)
- University Hospital Coventry NHS Trust, United Kingdom (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- TwoCan Associates (Collaboration)
- Institute for Oncology and Radiology of Serbia (Collaboration)
- Gynaecologic Oncology Group GOC (Collaboration)
- British Columbia Cancer Agency (BCCA) (Collaboration)
- University of Texas at San Antonio, United States (Collaboration)
- Auckland City Hospital (Collaboration)
- University of Colorado at Boulder, United States (Collaboration)
- Penn State Milton S. Hershey Medical Center (Collaboration)
- Laval Hospital (Collaboration)
- Dana-Farber Cancer Institute (Collaboration)
- UNLISTED (Collaboration)
- Guangdong General Hospital (Collaboration)
- Trondheim University Hospital (Collaboration)
- Freeman Hospital, Newcastle Upon Tyne, United Kingdom (Collaboration)
- The Christie NHS Foundation Trust, Manchester (Collaboration)
- Bordet Institute (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- Sunnybrook Health Sciences Centre (Collaboration)
- Canadian Cancer Society (Collaboration)
- University College London, United Kingdom (Collaboration)
- Duke University Health System (Collaboration)
- Cross Cancer Institute (Collaboration)
- University of Arizona, United States (Collaboration)
- Velindre Cancer Centre (Collaboration)
- Brussels Saint-Luc University Hospital (UCL) (Collaboration)
- University of Duisburg-Essen, Germany (Collaboration)
- Rene Gauducheau Centre (Collaboration)
- Germans University Hospital (Collaboration)
- Imperial Cancer Research Fund (Collaboration)
- Centre for Research and Implementation of Clinical Practice (Collaboration)
- University Hospitals Bristol NHS Foundation Trust (Collaboration)
- Academic Medical Center (Collaboration)
- Sanjay Gandhi Postgrad Inst Med Sciences (Collaboration)
- Crozer-Keystone Health System (Collaboration)
- Christiana Care Health System (Collaboration)
- Albany Medical College (Collaboration)
- University of Ghent, Belgium (Collaboration)
- St Woolos Hospital (Collaboration)
- Vanderbilt University, United States (Collaboration)
- Gülhane Military Medical Academy (GATA), Turkey (Collaboration)
- Centro Hospitalario Pereira Rossell CHPR (Collaboration)
- John H. Stroger Jr. Hospital (Collaboration)
- Hyogo College of Medicine (Collaboration)
- Royal North Shore Hospital (Collaboration)
- Thomas Jefferson University (Collaboration)
- Academy of Medical Royal Colleges (Collaboration)
- Chiba Cancer Center (Collaboration)
- Liverpool Womens NHS Foundation Trust (Collaboration)
- Tel Aviv University, Israel (Collaboration)
- Catalan Institute of Oncology (Collaboration)
- Cleveland Clinic (Collaboration)
- Queen Elizabeth Hospital Birmingham (Collaboration)
- European Organisation for Research and Treatment of Cancer (EORTC) (Collaboration)
- Universite Montpellier (Collaboration)
- Tygerberg Children’s Hospital (Collaboration)
- Pitié-Salpêtrière Hospital (Collaboration)
- University of Gothenburg, Sweden (Collaboration)
- Gustave-Roussy Institute (Collaboration)
- Smith and Nephew, United Kingdom (Collaboration)
- National Kyushu Cancer Center (Collaboration)
- Keele University, United Kingdom (Collaboration)
- Wilhelminen Hospital (Collaboration)
- Harvard University (Collaboration)
- Vejle Hospital (Collaboration)
- Osaka City General Hospital (Collaboration)
- University of Padova (Collaboration)
- University of Liverpool, United Kingdom (Collaboration)
- Helsinki University Central Hospital (Collaboration)
- Mansoura University (Collaboration)
- Netherlands Cancer Institute (Collaboration)
- Chiang Mai University (Collaboration)
- University Hospital La Paz (Collaboration)
- Oncology Institute of Vojvodina (Collaboration)
- Mario Negri Institute for Pharmacological Research (Collaboration)
- Cedars-Sinai Medical Center (Collaboration)
- Tokyo Medical and Dental University (Collaboration)
- Birmingham Heartlands Hospital (Collaboration)
- Yeshiva University (Collaboration)
- University of Glasgow, United Kingdom (Collaboration)
- Yale University (Collaboration)
- University of Rome II (Tor Vergata), Italy (Collaboration)
- Tohoku University (Collaboration)
- Korea Cancer Center Hospital (Collaboration)
- University of Sussex, United Kingdom (Collaboration)
- Leicester Royal Infirmary (Collaboration)
- Strasbourgs University Hospitals (Collaboration)
- Yokohama City University Medical Centre (Collaboration)
- University Hospitals of Leicester NHS, United Kingdom (Collaboration)
- University of Turku, Finland (Collaboration)
- Cancer Institute of the Loire (Collaboration)
- National Cancer Institute (NCI) (Collaboration)
- Nagoya University, Japan (Collaboration)
- University of Ancona (Collaboration)
- Cancer and Leukemia Group B (Collaboration)
- Churchill Hospital (Collaboration)
- Herlev Hospital (Collaboration)
- The Cochrane Collaboration (Collaboration)
- Queen Mary, University of London, United Kingdom (Collaboration)
- Glenfield Hospital (Collaboration)
- University of Bern (Collaboration)
- Cardiff University, United Kingdom (Collaboration)
- Sun Yat-Sen University (Collaboration)
- Princess Margaret Hospital (Collaboration)
- San Luigi Gonzaga Hospital (Collaboration)
- University of Maryland, United States (Collaboration)
- Royal Marsden NHS Foundation Trust (Collaboration)
- National Institute for Health Research, United Kingdom (Collaboration)
- Tata Memorial Hospital (Collaboration)
- Memorial Sloan Kettering Cancer Center (Collaboration)
- Karolinska Institute, Sweden (Collaboration)
- Tufts University (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- University of Cambridge, United Kingdom (Collaboration)
- Medical Research Council (Collaboration)
- University of York, United Kingdom (Collaboration)
- Kyoto University, Japan (Collaboration)
- Wake Forest University, United States (Collaboration)
- University College London Hospital (UCLH) NHS Foundation Trust (Collaboration)
- University of Iowa Hospitals and Clinics (Collaboration)
- Royal Prince Alfred Hospital (RPAH) Sydney (Collaboration)
- University Medical Center Gronigen (Collaboration)
- Beijing University of Chinese Medicine (Collaboration)
- Princess Margaret Cancer Centre (Collaboration)
- Liverpool School of Tropical Medicine (Collaboration)
- University Hospital of Besancon (Collaboration)
Publications
Vale CL
(2012)
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
in Cancer treatment reviews
Vale CL
(2012)
Evaluation of patient involvement in a systematic review and meta-analysis of individual patient data in cervical cancer treatment.
in Systematic reviews
Vale CL
(2010)
Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit.
in Clinical oncology (Royal College of Radiologists (Great Britain))
Vale CL
(2012)
Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
in The Cochrane database of systematic reviews
Vale CL, Tierney JF
(2006)
Concomitant chemoradiation for cervical cancer: a meta-analysis using individual patient data from randomised controlled trials
in International Journal of Gynecological Cancer
Van Dalen E
(2007)
Tips and tricks for understanding and using SR results. No. 7: time-to-event data
in Evidence-Based Child Health: A Cochrane Review Journal
| Guideline Title | Cancer Management Guidelines. Genitourinary. Bladder |
| Description | Bladder Adj CT IPD (PMID: 15939530) BCCA guideline 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Adjuvant chemotherapy is not routinely recommended". based on our systematic review and meta-analysis of IPD (PMID: 15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | Guidelines on bladder cancer. Muscle-invasive and metastatic |
| Description | Bladder Adj CT IPD (PMID: 15939530) EAU guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Adjuvant chemotherapy is advised within clinical trials, but not for routine use, because it has not been studied sufficiently" based on our systematic review and meta-analysis of IPD (PMID: 15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Description | Bladder Adj CT IPD (PMID: 16625650) ESMO guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice", based on our systematic review and meta-analysis of IPD (PMID: 16625650) |
| URL | http://europepmc.org/abstract/MED/16625650 |
| Guideline Title | New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification |
| Description | Bladder Adj CT IPD (PMID:15939530) AURO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Adjuvant chemotherapy is feasible but a related survival benefit has not yet been ultimately confirmed by moderate and high-quality studies", based on our systematic review and meta-analysis of IPD (PMID:15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | Guidelines on Bladder and Upper Urinary Tract Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) AURO.it guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Si suggerisce di non eseguire la chemioterapia adiuvante" "Nel 2005 il gruppo ABC ha condotto una metanalisi dei dati individuali di 491 pazienti dai sei studi clinici randomizzati condotti fino ad allora (di cui uno non pubblicato). Nonostante la limitazione della metanalisi dovuta al numero ridotto dei pazienti, al fatto che quattro dei 6 studi inclusi erano stati interrotti al momento della analisi ad interim, non permettendo così di trarre conclusioni definitive, è stata evidenziata una riduzione del rischio di morte del 25% (hazard ratio: 0.75; p=0.019) a favore del gruppo trattato con chemioterapia ma il dato è ancora controverso." Translation: "Use of adjuvant chemotherapy is not advised" "In 2005, the ABC group conducted an analysis of 491 patients from 6 RCTs, 5 published and 1 unpublished. Despite the limited number of patients and the early stopping of included trials, making it difficult to draw definitive conclusions, a 25% reduction in the risk of death was observed (HR: 0.75; p=0.019) in the group treated with adjuvant chemotherapy", based on our systematic review and meta-analysis of IPD (PMID: 15939530) |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is not enough evidence in favour of the routine use of adjuvant chemotherapy. The data are not convincing enough to give an unequivocal recommendation for the use of adjuvant chemotherapy", based on our systematic review and meta-analysis of IPD (PMID:15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Adjuvant chemotherapy is advised within clinical trials, but not for routine use", based on our systematic review and meta-analysis of IPD (PMID:15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939530) |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939530) |
| Guideline Title | Evidence-based clinical practice guidelines for bladder cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) JUA guideline 2010 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Perioperative chemotherapy might improve the therapeutic results for muscle-invasive bladder cancer. Preoperative and postoperative chemotherapy have their respective merits and demerits. At present, a definite improvement in survival rates has been shown only for preoperative cisplatin-based combination chemotherapy.(Grade of recommendation A.)", based on our systematic review and meta-analysis of IPD (PMID:15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15939530) |
| URL | http://europepmc.org/abstract/MED/15939530 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy", based on our systematic review and meta-analysis of IPD (PMID: 15939530) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy", based on our systematic review and meta-analysis of IPD (PMID: 15939530) |
| Guideline Title | SEOM clinical guidelines for the treatment of invasive bladder cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) SEOM guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15939530) |
| URL | http://europepmc.org/abstract/MED/21821489 |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Adj CT IPD (PMID:15939530; 16625650) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Available trials provide insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice [I, A].", based on our systematic review and meta-analysis of IPD (PMID:15939530; PMID:16625650) |
| URL | http://europepmc.org/abstract/MED/16625650 |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Adj CT IPD (PMID:15939530; 16625650) ESMO guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Available trials provide insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice [I, A].", based on our systematic review and meta-analysis of IPD (PMID:15939530; PMID:16625650) |
| URL | http://europepmc.org/abstract/MED/16625650 |
| Guideline Title | Clinical Practice Guideline: GU-002 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:16625650) AHS guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:16625650) |
| URL | http://europepmc.org/abstract/MED/16625650 |
| Guideline Title | Clinical Practice Guideline: GU-002 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:16625650) AHS guideline 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:16625650) |
| Guideline Title | Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Description | Bladder Adj CT IPD (PMID:16625650) ESMO guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:16625650) |
| URL | http://europepmc.org/abstract/MED/16625650 |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Adj CT IPD (PMID:16625650) ESMO guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "While there is still insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice [I, A], it is likely that high-risk patients, such as those with extravesical and/or node-positive disease that have not received neoadjuvant chemotherapy, will benefit most from adjuvant chemotherapy", based on our systematic review and meta-analysis of IPD (PMID:16625650) |
| Guideline Title | Guidelines on Bladder and Upper Urinary Tract Cancer |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) AURO.it guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Si suggerisce di considerare la chemioterapia neoadiuvante dopo discussione con il paziente a riguardo del rapporto costo/ beneficio" "Nel 2005 l'Advanced Bladder Cancer (ABC) Meta-analysis Collaboration ha condotto una metanalisi dei dati individuali di 3005 pazienti di 11 studi randomizzati (alcuni dei quali già considerati nella metanalisi di Winquist) di chemioterapia neoadiuvante + trattamento locale (radioterapia o cistectomia) versus trattamento locale [10] (H). Questa metanalisi, eccetto l'undicesimo studio successivamente inserito, era la rivalutazione di quella precedente pubblicata su Lancet nel 2003 [11] (H) relativa ai dati di 2688 pazienti di 10 studi clinici randomizzati che aveva evidenziato una riduzione del 13% del rischio di morte a favore della chemioterapia neoadiuvante (HR: 0.87; p=0.016). E' stato evidenziato un beneficio clinico associato alla chemioterapia neoadiuvante di combinazione "platinum-based" (HR= 0.86; p=0.003) con riduzione del 14% del rischio di morte, il che equivale ad un vantaggio assoluto di sopravvivenza del 5% e ad un vantaggio assoluto del 9% in termini di "disease-free survival" a 5 anni (HR: 0.78; p<0.0001), indipendentemente dal tipo di trattamento locale eseguito e dai sottogruppi di pazienti considerati." Translation: "Use of noeadjuvant chemotherapy should be considered after discussions with the patient with respect to the cost/benefit of treatment" "In 2005 the ABC Meta-analysis Collaboration conducted an IPD meta-analysis based on 3005 patients from 11 RCTs, looking at neoadjuvant chemotherapy + local treatment (radiotherapy or cystectomy) versus local treatment. This meta-analysis was an update of the one published in the Lancet in 2003, including an additional study. The Lancet 2003 study was based on 2688 patients from 10 RCTs and showed a 13% reduction in the risk of death with neoadjuvant chemotherapy (HR=0.87; p=0.016). There was a clinical benefit associated with platinum-based combination chemotherapy with a 14% reduction in the risk of death (HR=0.86; p=0.003) which is equivalent to a 5% absolute survival benefit and a 9% disease-free survival benefit at 5 years (HR=0.78; p<0.0001), independent of the type of local treatment received and across all patient subgroups.", based on our systematic review and meta-analysis of IPD (PMID: 12801735; PMID: 15939524) |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:12801735; PMID:15939524) |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Neoadjuvant cisplatin-containing combination chemotherapy improves overall survival (5-8% at 5 years)," based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| Guideline Title | Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial urinary bladder cancer |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) SOS/SUA guideline 2014 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Neo-adjuvant cisplatin based chemotherapy improved overall survival by 5-7% at 5 years and this option should be offered to patients especially with locally advanced disease (T3, T4)(EL-1)", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| Guideline Title | Guidelines on bladder cancer. Muscle invasive and metastatic |
| Description | Bladder Neo CT IPD (PMID: 12801735; PMID: 15939524) EAU guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Cisplatin containing combination neoadjuvant chemotherapy should be considered for muscle invasive bladder cancer irrespective of definitive treatment" based on our systematic review and meta-analysis of IPD (PMID: 12801735; PMID: 15939524) |
| URL | http://europepmc.org/abstract/MED/12801735 |
| Guideline Title | Clinical Practice Guideline: GU-002 Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID: 15846746) AHS guideline 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "All patients who are eligible for cisplatinum-based combination chemotherapy should have the opportunity to discuss neoadjuvant therapy with a medical oncologist either before surgery or as combined modality therapy", based on our systematic review and meta-analysis of IPD (PMID:15846746) |
| Guideline Title | Invasive bladder cancer: ESMO clinical recommendations of diagnosis, treatment and follow-up |
| Description | Bladder Neo CT IPD (PMID: 15846746) ESMO guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The demonstrated survival benefit encourages the use of platinum-based combination chemotherapy for patients with invasive bladder cancer before radical cystectomy or definitive radiotherapy" based on our systematic review and meta-analysis of IPD (PMID: 15846746) |
| URL | http://europepmc.org/abstract/MED/15846746 |
| Guideline Title | Cancer Management Guidelines. Genitourinary. Bladder |
| Description | Bladder Neo CT IPD (PMID: 15939524) BCCA guideline 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15939524) |
| URL | http://europepmc.org/abstract/MED/15939524 |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Neo CT IPD (PMID: 15939524) ESMO guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The use of cisplatin-based neoadjuvant chemotherapy for bladder cancer is supported by a meta-analysis of 11 randomised trials including 3005 patients. There was a 5% absolute increase in 5-year OS and a 9% absolute increase in 5-year disease-free survival (DFS) compared with RC alone. This demonstrated survival benefit encourages the use of platinum-based combination chemotherapy before RC or definitive radiotherapy [I, A]", based on our systematic review and meta-analysis of IPD (PMID: 15939524) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Randomized trials and meta-analyses show a survival benefit for cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive bladder cancer. Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy. Neoadjuvant chemotherapy is preferred over adjuvant-based chemotherapy on a higher level of evidence data", based on our systematic review and meta-analysis of IPD (PMID: 15939524) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Randomized trials and meta-analyses show a survival benefit for cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive bladder cancer. Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy. Neoadjuvant chemotherapy is preferred over adjuvant-based chemotherapy on a higher level of evidence data", based on our systematic review and meta-analysis of IPD (PMID: 15939524) |
| Guideline Title | SEOM clinical guidelines for the treatment of invasive bladder cancer |
| Description | Bladder Neo CT IPD (PMID:12801735) SEOM guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:12801735) |
| URL | http://europepmc.org/abstract/MED/21821489 |
| Guideline Title | New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification |
| Description | Bladder Neo CT IPD (PMID:12801735; 15939524) AURO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "High-quality clinical evidence shows that neoadjuvant cisplatin-based chemotherapy has acceptable toxicity and increases the survival rate by 5-6.5% in patients with T2-T2/N0-N2/M0 clinical stage disease", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| URL | http://europepmc.org/abstract/MED/12801735 |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID:12801735; 15939524) EAU guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Neoadjuvant cisplatin-containing combination chemotherapy should be considered in muscleinvasive bladder cancer, irrespective of definitive treatment", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| URL | http://europepmc.org/abstract/MED/12801735 |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID:12801735; 15939524) EAU guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Neoadjuvant cisplatin-containing combination chemotherapy should be considered in muscleinvasive bladder cancer, irrespective of further treatment", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| URL | http://europepmc.org/abstract/MED/12801735 |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID:12801735; 15939524) EAU guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Neoadjuvant cisplatin-containing combination chemotherapy improves overall survival, irrespective of the type of definitive treatment used", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| URL | http://europepmc.org/abstract/MED/12801735 |
| Guideline Title | Saudi Oncology Society clinical management guidelines for urinary bladder cancer |
| Description | Bladder Neo CT IPD (PMID:12801735; 15939524) SOS guideline 2011 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Neoadjuvant cisplatin-based chemotherapy improved overall survival by 5-7% at 5 years and this option should be offered to patients especially with locally advanced disease (T3,T4)", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| URL | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099485/ |
| Guideline Title | Bladdercarcinoma: Nation-wide guideline, Version: 1.0 |
| Description | Bladder Neo CT IPD (PMID:15846746) ACCC guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is no standard indication for administration of neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma", based on our systematic review and meta-analysis of IPD (PMID: 15846746) |
| URL | http://europepmc.org/abstract/MED/15846746 |
| Guideline Title | Clinical Practice Guideline: GU-002 Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID:15846746) AHS guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15846746) |
| URL | http://europepmc.org/abstract/MED/15846746 |
| Guideline Title | Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Description | Bladder Neo CT IPD (PMID:15846746) ESMO guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Two large randomized trials and a meta-analysis support the use of neo-adjuvant chemotherapy before cystectomy for T2 and T3 disease", based on our systematic review and meta-analysis of IPD (PMID: 15846746) |
| URL | http://europepmc.org/abstract/MED/15846746 |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Neo CT IPD (PMID:15846746) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis supports the use of neoadjuvant chemotherapy before cystectomy for T2 and T3 disease. The demonstrated survival benefit encourages the use of platinum-based combination chemotherapy before radical cystectomy or definitive radiotherapy [I, A].", based on our systematic review and meta-analysis of IPD (PMID:15846746) |
| URL | http://europepmc.org/abstract/MED/15846746 |
| Guideline Title | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Bladder Neo CT IPD (PMID:15846746) ESMO guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis supports the use of neoadjuvant chemotherapy before cystectomy for T2 and T3 disease. The demonstrated survival benefit encourages the use of platinum-based combination chemotherapy before radical cystectomy or definitive radiotherapy [I, A].", based on our systematic review and meta-analysis of IPD (PMID:15846746) |
| URL | http://europepmc.org/abstract/MED/15846746 |
| Guideline Title | The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID:15939524) EAU guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "As a result of a 5-8 % overall survival (OS) advantage in recently published studies and meta-analyses, it has therefore been recommended that neoadjuvant cisplatin containing combination chemotherapy should be considered in muscle-invasive BCa irrespective of definitive treatment (grade of recommendation: A)", based on our systematic review and meta-analysis of IPD (PMID:15939524) |
| URL | http://europepmc.org/abstract/MED/15939524 |
| Guideline Title | Evidence-based clinical practice guidelines for bladder cancer |
| Description | Bladder Neo CT IPD (PMID:15939524) JUA guideline 2010 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Perioperative chemotherapy might improve the therapeutic results for muscle-invasive bladder cancer. Preoperative and postoperative chemotherapy have their respective merits and demerits. At present, a definite improvement in survival rates has been shown only for preoperative cisplatin-based combination chemotherapy.(Grade of recommendation A.)", based on our systematic review and meta-analysis of IPD (PMID: 15939524) |
| URL | http://europepmc.org/abstract/MED/15939524 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.2.2010 Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID:15939524) NCCN guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In the most recent meta-analysis, a statistically significant decrease in the death rate was seen corresponding to an improvement in overall survival. The NCCN Bladder Cancer panel members recommend considering cisplatin-based neoadjuvant combination chemotherapy", based on our systematic review and meta-analysis of IPD (PMID:15939524) |
| URL | http://europepmc.org/abstract/MED/15939524 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.2.2011 Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID:15939524) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In the most recent meta-analysis, a statistically significant decrease in the death rate was seen corresponding to an improvement in overall survival.46 The NCCN Bladder Cancer panel members recommend considering cisplatin-based neoadjuvant combination chemotherapy (Category 1 recommendation for T3 lesions and category 2A for T2 lesions).", based on our systematic review and meta-analysis of IPD (PMID: 15939524) |
| URL | http://europepmc.org/abstract/MED/15939524 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Bladder Cancer |
| Description | Bladder Neo CT IPD (PMID:15939524) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939524) |
| URL | http://europepmc.org/abstract/MED/15939524 |
| Guideline Title | NCCN Practice Gudelines in Oncology - v.1.2010 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID: 19001332) NCCN guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | The NCCN panel agrees that RT and concurrent cisplatin-based chemotherapy (either cisplatin alone or cisplatin/5-fluorouracil [5-FU]) are the treatment of choice for stages IIB, IIIA, IIIB and IVA disease, based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v1.0 2014 |
| Description | Cervix CTRT IPD (PMID: 19001332, PMID: 20091664) GGPO guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332, PMID: 20091664) |
| Guideline Title | ACR Appropriateness Criteria ADVANCED CERVICAL CANCER |
| Description | Cervix CTRT IPD (PMID:19001332) ACR guideline 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | ACR Appropriateness Criteria ADVANCED CERVICAL CANCER |
| Description | Cervix CTRT IPD (PMID:19001332) ACR guideline advanced 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The addition of chemotherapy concurrently with RT has resulted in a large improvement in overall survival", based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| Guideline Title | ACR Appropriateness Criteria Definitive therapy for early stage cervical cancer |
| Description | Cervix CTRT IPD (PMID:19001332) ACR guideline early 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | Cancer of the Uterine Cervix |
| Description | Cervix CTRT IPD (PMID:19001332) AHS guideline 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis of 13 trials showed that chemoradiotherapy (versus radiotherapy alone) increased the disease free survival rate at five years by eight percent."; "Cisplatin should be administered at a dose of 40 mg/m2 (max = 80) intravenously over one hour weekly for 5 - 6 cycles during EBRT", based on our systematic review and meta-analysis of summary data (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | Cancer of the Uterine Cervix |
| Description | Cervix CTRT IPD (PMID:19001332) AHS guideline 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Cisplatin should be administered at a dose of 40 mg/m2 (max = 80) intravenously over one hour weekly for 5 - 6 cycles during EBRT", based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| Guideline Title | A national clinical practice guideline for the management of cervical cancer |
| Description | Cervix CTRT IPD (PMID:19001332) BHKC guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix CTRT IPD (PMID:19001332) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concomitant chemoradiation represents the standard. This modality is superior to radiotherapy alone for local control, metastases rate, disease-free and overall survival", based on our systematic review and meta-analysis of summary data (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix CTRT IPD (PMID:19001332) ESMO guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2011 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2012 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| URL | http://europepmc.org/abstract/MED/19001332 |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2012 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2014 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| Guideline Title | Provincial Cervical Cancer Treatment Guidelines |
| Description | Cervix CTRT IPD (PMID:19001332) SCA guideline 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332) |
| Guideline Title | SEOM guidelines for cervical cancer |
| Description | Cervix CTRT IPD (PMID:19001332) SEOM guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Stages IIB, III and IVA: This category has traditionally included patients with stage IIB-IVA disease. However, currently patients with IB2 and IIA2 disease are also included in this category. Concomitant chemoradiation represents the standard treatment. This modality is superior to RT alone for local control, metastasis rate, disease-free and overall survival. A meta-analysis based on 18 trials with individual patient data was recently performed. Cisplatin-based chemotherapy was used in 85% of the patients. The most common regimen was cisplatin monotherapy 40 mg/m2 on a weekly schedule.The results demonstrated a 6% and 8% improvement in absolute 5-year survival and disease-free survival with chemoradiotherapy respectively. In addition a decreasing relative effect of chemoradiotherapy on survival with increasing tumour stage was observed, with estimated absolute survival benefits of 10% (stage Ia to IIA), 7% (stage IIB) and 3% (stage III to IVA) at 5 years", based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| Guideline Title | Cervical cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Description | Cervix CTRT SR (PMID: 11564482) ESMO guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concomitant chemoradiation represents the standard. This modlity is suprior to radiotherapy alone for local control, metastases rate, diease-free and overall survival", based on our systematic review and meta-analysis of summary data (PMID: 11564482) |
| URL | http://europepmc.org/abstract/MED/11564482 |
| Guideline Title | Cervical Cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Description | Cervix CTRT SR (PMID: 11564482) ESMO guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concomitant chemoradiation represents the standard. This modality is superior to radiotherapy alone for local control, metastases rate, disease-free and overall survival", based on our systematic review and meta-analysis of summary data (PMID: 11564482) |
| URL | http://europepmc.org/abstract/MED/11564482 |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v1.0 2014 |
| Description | Cervix CTRT SR (PMID: 16034873) GGPO guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Bei der Patientin mit Zervixkarzinom soll bei Indikationsstellung zu einer primären Radiotherapie ab Stadium IB2 diese in Kombination mit einer cisplatinbasierten Chemotherapie erfolgen.", based on our systematic review and meta-analysis of summary data (PMID: 16034873) |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix CTRT SR (PMID:11564482) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concomitant chemoradiation represents the standard. This modality is superior to radiotherapy alone for local control, metastases rate, disease-free and overall survival", based on our systematic review and meta-analysis of summary data (PMID: 11564482) |
| URL | http://europepmc.org/abstract/MED/11564482 |
| Guideline Title | SIGN99 Management of cervical cancer. A national clinical guideline |
| Description | Cervix CTRT SR (PMID:11564482) SIGN guideline 2008 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Any patient with cervical cancer considered suitable for radical radiotherapy treatment should have concurrent chemoradiotherapy with a platinum based chemotherapy, if fit enough" based on our systematic review and meta-analysis of summary data (PMID: 11564482) |
| URL | http://www.sign.ac.uk/pdf/sign99.pdf |
| Guideline Title | A national clinical practice guideline for the management of cervical cancer |
| Description | Cervix CTRT SR (PMID:16034873) BHKC guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID:16034873) |
| URL | http://europepmc.org/abstract/MED/16034873 |
| Guideline Title | ACR Appropriateness Criteria ADVANCED CERVICAL CANCER |
| Description | Cervix Neo CT IPD (PMID:14602133) ACR guideline advanced 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 14602133) |
| URL | http://europepmc.org/abstract/MED/14602133 |
| Guideline Title | ACR Appropriateness Criteria ADVANCED CERVICAL CANCER |
| Description | Cervix Neo CT IPD (PMID:14602133) ACR guideline advanced 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 14602133) |
| Guideline Title | ACR Appropriateness Criteria Definitive therapy for early stage cervical cancer |
| Description | Cervix Neo CT IPD (PMID:14602133) ACR guideline early 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 14602133) |
| URL | http://europepmc.org/abstract/MED/14602133 |
| Guideline Title | A national clinical practice guideline for the management of cervical cancer |
| Description | Cervix Neo CT IPD (PMID:14602133) BHKC guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "If NACT prior to surgery is chosen to treat patients with FIGO stage IB2, IIA, or IIB cervical cancer, then short cycle (= 14 days) and dose-intensive regimens (cisplatin = 25 mg/m2) are recommended (1B)", based on our systematic review and meta-analysis of IPD (PMID: 14602133) |
| URL | http://europepmc.org/abstract/MED/14602133 |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix Neo CT IPD (PMID:14602133) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 14602133) |
| URL | http://europepmc.org/abstract/MED/14602133 |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix Neo CT IPD (PMID:15106161) ESMO guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15106161) |
| URL | http://europepmc.org/abstract/MED/15106161 |
| Guideline Title | ACR Appropriateness Criteria ADVANCED CERVICAL CANCER |
| Description | Cervix Neo CT SR (PMID:20091632) ACR guideline advanced 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 20091632) |
| URL | http://europepmc.org/abstract/MED/20091632 |
| Guideline Title | ACR Appropriateness Criteria ADVANCED CERVICAL CANCER |
| Description | Cervix Neo CT SR (PMID:20091632) ACR guideline advanced 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 20091632) |
| Guideline Title | ACR Appropriateness Criteria Definitive therapy for early stage cervical cancer |
| Description | Cervix Neo CT SR (PMID:20091632) ACR guideline early 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The appropriateness of induction chemotherapy followed by surgery remains uncertain, and it should be performed only in the context of a clinical trial", based on our systematic review and meta-analysis of summary data (PMID: 20091632) |
| URL | http://europepmc.org/abstract/MED/20091632 |
| Guideline Title | A national clinical practice guideline for the management of cervical cancer |
| Description | Cervix Neo CT SR (PMID:20091632) BHKC guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 20091632) |
| URL | http://europepmc.org/abstract/MED/20091632 |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2014 Cervical Cancer |
| Description | Cervix Neo CT SR (PMID:20091632) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer. The panel does not recommend the use of neoadjuvant chemotherapy", based on our systematic review and meta-analysis of summary data (PMID: 20091632) |
| Description | Cervix Neo CT SR (PMID:20091632) NICE QIPP topic 2011 |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | This case study, published by NICE is aimed at informing the decisions of local initiatives about patient care or the use of resources, and is based on our systematic review and meta-analysis of summary data (PMID: 20091632) |
| URL | http://europepmc.org/abstract/MED/20091632 |
| Guideline Title | S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v1.0 2014 |
| Description | Cervix Neo CT SR (PMID:23235641) GGPO guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Eine medikamentöse neoadjuvante Therapie kann bei ausgewählten Risikopatientinnen durchgeführt werden.", based on our systematic review and meta-analysis of summary data (PMID: 23235641) |
| Guideline Title | COLON CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP |
| Description | Colorectal Anti-EGFR SR (PMID:22118887) BHKC guideline 2014 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "KRAS mutation status is an effect modifier for anti-EGFR antibodies, with the efficacy of anti-EGFR antibodies limited to KRAS wild type patients. The systematic reviews by Vale et al. and Adelstein et al. confirmed this result", based on our systematic review and meta-analysis of summary data (PMID: 22118887) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2013. Colon Cancer |
| Description | Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer", based on our systematic review and meta-analysis of summary data (PMID: 22118887) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2013. Colon Cancer |
| Description | Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer", based on our systematic review and meta-analysis of summary data (PMID: 22118887) |
| Guideline Title | Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Endometrial CT SR (PMID:16034916) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Reasonable to consider adjuvant chemotherapy for high-grade (grade 3) tumours", based on our systematic review and meta-analysis of summary data (PMID: 16034916) |
| URL | http://europepmc.org/abstract/MED/16034916 |
| Guideline Title | Clinical Practice GuidelineGYNE-002: Endometrial Cancer |
| Description | Endometrial CT SR (PMID:17150999) AHS guideline 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Humber, et al. 38 in 2007 concluded that combination chemotherapy was superior to single agent chemotherapy, with the addition of anthracyclines and taxanes to cisplatin giving the best response. Many studies since then have shown the superiority of carboplatin with paclitaxel, both in response and toxicity profile", based on our systematic review and meta-analysis of summary data (PMID: 17150999) |
| URL | http://europepmc.org/abstract/MED/17150999 |
| Guideline Title | ENDOMETRIAL CANCER CLINICAL PRACTICE GUIDELINE GYNE-002 |
| Description | Endometrial CT SR (PMID:17150999) AHS guideline 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "..a meta-analysis by Humber, et al.in 2007 concluded that combination chemotherapy was superior to single agent chemotherapy, with the addition of anthracyclines and taxanes to cisplatin giving the best response.", based on our systematic review and meta-analysis of summary data (PMID: 17150999) |
| Guideline Title | Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit |
| Description | Endometrial CT SR (PMID:17150999) AOSCG guideline 2009 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999) |
| URL | http://europepmc.org/abstract/MED/17150999 |
| Guideline Title | Clinical practice guidelines for the treatment and management of endometrial cancer |
| Description | Endometrial CT SR (PMID:17150999) CCA guideline 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999) |
| Guideline Title | Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Endometrial CT SR (PMID:17150999) ESMO guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999) |
| URL | http://europepmc.org/abstract/MED/17150999 |
| Guideline Title | Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Endometrial CT SR (PMID:17150999) ESMO guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2014. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated", based on our systematic review and meta-analysis of summary data (PMID: 17150999) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2011. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline UterineNeoplasms 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999) |
| URL | http://europepmc.org/abstract/MED/17150999 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2012. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline UterineNeoplasms 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999) |
| URL | http://europepmc.org/abstract/MED/17150999 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2013. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline UterineNeoplasms 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Chemotherapy for endometrial cancer has been extensively studied. Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated. Single-agent therapy can also be used", based on our systematic review and meta-analysis of summary data (PMID: 17150999) |
| Guideline Title | Systemic Therapy for Advanced or Recurrent Endometrial Cancer, and Advanced or Recurrent Uterine Papillary Serous Carcinoma |
| Description | Endometrial CT SR (PMID:17150999; 22895938) CCO guideline 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999; PMID: 22895938) |
| Guideline Title | Adjuvant systemic chemotherapy following surgery and external beam radiotherapy for adults with newly diagnosed malignant glioma |
| Description | Glioma CT IPD (PMID: 11937180) CCO guideline 2006 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Description | Glioma CT IPD (PMID: 11937180) ESMO guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Nitrosourea-based chemotherapy may marginally improve survival in selected patients" based on our systematic review and meta-analysis of IPD (PMID: 11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | Gliomas: Nation-wide guideline, Version: 2.0 |
| Description | Glioma CT IPD (PMID:11937180) ACCC guideline 2007 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | Anaplastic Astrocytomas and Oligodendrogliomas |
| Description | Glioma CT IPD (PMID:11937180) AHS guideline 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In a thorough systematic review and meta-analysis published by the Glioma Meta-analysis Trialists Group in 2002, individual patient data from 12 randomized controlled trials that compared radiotherapy alone with radiotherapy plus chemotherapy over a 30 year period were analyzed. In total, data from 3004 patients, 706 of which were patients with anaplastic astrocytomas, were included in the analysis, and the majority of the trials involved nitrosourea-based chemotherapy regimens. The group reported a small but statistically significant improvement in overall survival associated with the administration of adjuvant chemotherapy (HR=0.85, 95% CI 0.78 - 0.91; p<0.0001)", based on our systematic review and meta-analysis of IPD (PMID:11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | Clinical practice guidelines for the management of adult gliomas: astrocytomas and oligodendrogliomas |
| Description | Glioma CT IPD (PMID:11937180) CCA guideline 2009 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Adjuvant chemotherapy after surgery and radiotherapy provides modest improvement in progression free survival and overall survival for patients with GBM. Adjuvant chemotherapy after surgery and radiotherapy improves survival and is recommended for patients with anaplastic astrocytoma (AA).", based on our systematic review and meta-analysis of IPD (PMID:11937180) |
| Guideline Title | Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Description | Glioma CT IPD (PMID:11937180) ESMO guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Based on a large meta-analysis [Evidence level:IA] nitrosourea-based chemotherapy may marginally improve survival in selected patients", based on our systematic review and meta-analysis of IPD (PMID:11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Glioma CT IPD (PMID:11937180) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Based on a large meta-analysis [I, A] nitrosourea-based chemotherapy marginally improves survival", based on our systematic review and meta-analysis of IPD (PMID:11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.2.2011 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The Glioma Meta-Analysis Trialists Group reviewed 12 studies involving approximately 3000 patients and reported an absolute increase in 1-year survival from 40% to 46% and a 2-month increase in median survival when chemotherapy was added to postoperative radiation (HR, 0.85; 95% CI, 0.78-0.91; P<0.0001)", based on our systematic review and meta-analysis of IPD (PMID:11937180) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2012 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180) |
| Guideline Title | Improving Outcomes for People with Brain and Other CNS Tumours |
| Description | Glioma CT IPD (PMID:11937180) NICE guideline 2006 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Chemotherapy in an adjuvant setting has been the subject of a recent, high-quality meta-analysis. The meta-analysis included 12 RCTs, representing numerous chemotherapy regimens and demonstrated a 2-month median survival advantage for chemotherapy plus radiotherapy compared with radiotherapy alone (hazard ratio [HR] 0.85; 95% confidence interval [CI] 0.78 to 0.91; p = 0.00004) and a 5% increase in 2-year survival", based on our systematic review and meta-analysis of IPD (PMID: 11937180) |
| Guideline Title | SEOM guideline for the treatment of malignant glioma |
| Description | Glioma CT IPD (PMID:11937180) SEOM guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Chemotherapy increases survival and reduces the risk of death in 15% according to a meta-analysis performed in 3000 patients", based on our systematic review and meta-analysis of IPD (PMID:11937180) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2010 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180; 12519620) NCCN guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180, PMID:12519620) |
| URL | http://europepmc.org/abstract/MED/11937180 |
| Guideline Title | Treatment of Stage I & II Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Description | Lung Adj CT IPD (PMID:20338628) ACCP guideline stage I&II 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628) |
| Guideline Title | American College of Radiology ACR Appropriateness Criteria® INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER |
| Description | Lung Adj CT IPD (PMID:20338628) ACR guideline N2 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Adjuvant chemotherapy is the standard of care in patients with completely resected stage II and III NSCLC based on multiple randomized phase III trials and meta-analyses. Generally, the absolute OS benefit with chemotherapy at 5 years has been ~4%-15% with the most recent meta-analyses showing a 4%-5% benefit across all stages. This includes stage IIIA patients for whom the 5-year absolute survival benefit was also only 5% (95% confidence interval [CI], 3%-8%)", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP |
| Description | Lung Adj CT IPD (PMID:20338628) BHKC guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "NICE recommends to offer postoperative chemotherapy to patients with good performance status (WHO 0 or 1) and T1-3 N1-2 M0 NSCLC and to consider postoperative chemotherapy in patients with good performance status (WHO 0 or 1) and T2-3 N0 M0 NSCLC with tumours greater than 4 cm in diameter. They also recommend to offer a cisplatin-based combination chemotherapy regimen for adjuvant chemotherapy and to ensure eligible patients have the benefit of detailed discussion of the risks and benefits of adjuvant chemotherapy They base their conclusions on five systematic reviews with meta-analyses", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Adj CT IPD (PMID:20338628) CCA guideline stage II CT after operable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?" |
| Description | Lung Adj CT IPD (PMID:20338628) CCA guideline stage II after 2013 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | In patients with operable stage II NSCLC, the evidence supports the use of 3-4 cycles of adjuvant cisplatin based chemotherapy", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung Adj CT IPD (PMID:20338628) ESMO guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Chemotherapy is an integral part in the treatment of locally advanced NSCLC (LA-NSCLC) as it improves survival in all subgroups of patients, whether treated with surgery or radiotherapy, as shown in meta-analyses based on individual patient data [I, A]" "Adjuvant chemotherapy should be offered to patients with resected stage II or III NSCLC [I, A]", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The panel recommends chemotherapy (category I ) for patients with negative surgical margins and stage II disease 1) Tlab-2a, N1; 2) T2b, N1; or 3) T3, NO disease", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| URL | http://europepmc.org/abstract/MED/20338628 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The panel recommends chemotherapy (category I ) for patients with negative surgical margins and stage II disease 1) Tlab-2a, N1; 2) T2b, N1; or 3) T3, NO disease", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The panel recommends chemotherapy (category I) for patients with negative surgical margins and stage II disease 1) Tlab-2a, N1; 2) T2b, N1; or 3) T3, NO disease", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | NICE guideline CG121:The diagnosis and treatment of lung cancer (update of NICE clinical guideline 24). |
| Description | Lung Adj CT IPD (PMID:20338628) NICE guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Surgery in combination with adjuvant chemotherapy was associated with longer survival (hazard ratio = .86) than surgery alone. The results also suggest that patients who received adjuvant chemotherapy experienced longer recurrence-free survival with longer time to both loco-regional and distant recurrence"; "Consider postoperative chemotherapy in patients with good performance status (WHO 0 or 1) and T2-3 N0 M0 NSCLC with tumours greater than 4 cm in diameter", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| URL | http://www.nice.org.uk/CG121 |
| Guideline Title | SIGN 137: Management of Lung cancer |
| Description | Lung Adj CT IPD (PMID:20338628) SIGN 137 guideline 2014 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Postoperative SACT in patients with completely resected stage II to IIIa NSCLC confers an overall survival advantage of around 4% at five years (HR 0.86, 95% CI 0.8 to 0.92)." "Patients with good performance status (PS 0-1) who have completely resected NSCLC (stage II to IIIa) should be offered platinum based postoperative systemic anticancer therapy", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 |
| Description | Lung CT 95 IPD (PMID: 7580546) AOSCG guideline 2009 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Multiple individual randomised studies and several meta-analyses have shown a survival benefit for systemic chemotherapy compared with best supportive care in patients with good performance status. Alkylating-agent based chemotherapy, however, was associated with a detrimental effect on survival. In a recent updated meta-analysis, based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Cancer Management Guidelines. Lung (including Mesothelioma & Thymoma) (6.1.04) |
| Description | Lung CT 95 IPD (PMID: 7580546) BCCA guideline 6.1.04 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD is used as evidence throughout this guideline for all stages of non-small cell lung cancer (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | ERS/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients (surgery and chemo-radiotherapy) |
| Description | Lung CT 95 IPD (PMID: 7580546) ERS/ESTS guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. |
| Description | Lung CT 95 IPD (PMID: 7580546) ESMO guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2010. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID: 7580546) NCCN guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Treatment of Stage I & II Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Description | Lung CT 95 IPD (PMID:7580546) ACCP guideline stage I&II 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Description | Lung CT 95 IPD (PMID:7580546) ACCP guideline stage III 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "We recommend adjuvant chemotherapy for patients with completely resected NSCLC with incidentally detected stage III disease unless there is reason to believe the risk of chemotherapy related complications is unusually high on the basis of performance status or comorbidities", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | Treatment of non-small cell lung cancer, stage IIIA. ACCP evidence-based clinical practice guidelines (2nd edition) |
| Description | Lung CT 95 IPD (PMID:7580546) ACCP guideline stage IIIA 2007 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In patients with resected NSCLC who were found to have incidental (occult) N2 disease (IIIA1-2) and who have good performance status, adjuvant platinum- based chemotherapy is recommended", based on our systematic review and meta-analysis of IPD (PMID: 7580546) and subsequent large trials |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Treatment of non-small cell lung cancer, stage IIIB. ACCP evidence-based clinical practice guidelines (2nd edition) |
| Description | Lung CT 95 IPD (PMID:7580546) ACCP guideline stage IIIB 2007 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IIIB disease without malignant pleural effusions, PS of 0 or 1, and minimal weight loss (<5%), platinum based combination chemoradiotherapy is recommended", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | ACR Appropriateness Criteria INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER |
| Description | Lung CT 95 IPD (PMID:7580546) ACR guideline Induction/Adjuvant 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: GOOD PERFORMANCE STATUS/DEFINITIVE INTENT |
| Description | Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgGoodPS 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "These analyses have provided the evidence that has established combined platinum-based chemotherapy and radiation as the standard of care for the good-performance-status patient with unresectable stage IIIA and IIIB NSCLC and minimal weight loss", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | American College of Radiology ACR Appropriateness Criteria® NONSURGICAL TREATMENT FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER: GOOD PERFORMANCE STATUS/DEFINITIVE INTENT |
| Description | Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgGoodPS 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Several meta-analyses have now examined the benefit of adding chemotherapy to radiation for stage IIIA and IIIB NSCLC. The Non-small Cell Lung Cancer Collaborative Group analyzed updated individual patient data from 22 trials including 3,033 patients. The group excluded all trials in which chemotherapy was given only during RT. Five trials used long-term alkylating agents, mainly cyclophosphamide or nitrosourea in combination with methotrexate. Three used vinca alkaloids or etoposide, and 3 used "other" regimens, mostly based on doxorubicin. Eleven trials used chemotherapy regimens containing cisplatin. The group found a significant overall benefit of chemotherapy, which resulted in a 10% reduction in the risk of death, corresponding to absolute benefits of 3% at 2 years and 2% at 5 years. Trials using cisplatin-based chemotherapy gave the strongest evidence in favor of chemotherapy, with absolute benefits of 4% at 2 years and 2% at 5 years", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POOR PERFORMANCE STATUS/PALLIATIVE INTENT |
| Description | Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgPoorPS 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POOR PERFORMANCE STATUS/PALLIATIVE INTENT |
| Description | Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgPoorPS 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | The British Collaborative Group showed a 27% reduction in the risk of death and a 10% improvement in survival in 1 year based on our systematic review and meta-analysis of IPD(PMID:7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POSTOPERATIVE ADJUVANT THERAPY IN NON-SMALL CELL LUNG CANCER |
| Description | Lung CT 95 IPD (PMID:7580546) ACR guideline PostOpAdj 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Non-Small Cell Lung Cancer Stage IV |
| Description | Lung CT 95 IPD (PMID:7580546) AHS guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Non-Small Cell Lung Cancer Stage IV |
| Description | Lung CT 95 IPD (PMID:7580546) AHS guideline stage IV 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Associazione Italiana di Oncologia Toracica |
| Description | Lung CT 95 IPD (PMID:7580546) AIOT guideline Stage I&II 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIa |
| Description | Lung CT 95 IPD (PMID:7580546) AIOT guideline Stage IIIa 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb-IV |
| Description | Lung CT 95 IPD (PMID:7580546) AIOT guideline Stage IIIb-IV 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline |
| Description | Lung CT 95 IPD (PMID:7580546) ASCO/CCO joint guideline 2007 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The 1995 NSCLC Collaborative Group individual-patient meta-analysis (n_9,387) found a statistically significant survival disadvantage associated with the use of postoperative chemotherapy involving alkylating agents", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 04) Post-operative Adjuvant Chemotherapy for Resected NSCLC |
| Description | Lung CT 95 IPD (PMID:7580546) BCCA guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 14) Palliative Chemotherapy of Advanced NSCLC |
| Description | Lung CT 95 IPD (PMID:7580546) BCCA guideline 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Cancer Management Guidelines. Lung (including Mesothelioma & Thymoma): Combined Modality Therapy for Unresectable Stage III (6.1.06) |
| Description | Lung CT 95 IPD (PMID:7580546) BCCA guideline 6.1.06 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The strongest evidence regarding combined modality therapy is derived from a meta-analysis of 52 randomized trials conducted by the Non-small Cell Lung Cancer Collaborative Group.1 Twenty-two trials were identified that compared radical radiation to radical radiation plus chemotherapy, of which eleven employed chemotherapy regimens including cisplatin. The addition of cisplatin-based chemotherapy to thoracic irradiation led to a 13% reduction in the risk of death, although the absolute survival advantage at 2 years was a modest 4%.", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Cancer Management Guidelines. Lung (including Mesothelioma & Thymoma): Palliative Chemotherapy of Advanced NSCLC (6.1.14) |
| Description | Lung CT 95 IPD (PMID:7580546) BCCA guideline 6.1.14 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is evidence from meta-analyses of a small survival benefit of chemotherapy over best supportive care in performance status 0-2 NSCLC patients", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Radical Management of Patients with Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) BTS/SCTS joint guideline 2010 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?" |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II after 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | In patients with operable stage II NSCLC, the evidence supports the use of 3-4 cycles of adjuvant cisplatin based chemotherapy; analysis. This study also revealed combination of alkylating agents with Cisplatin to be detrimental and this combination is no longer recommended", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?" |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II before 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | First-line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Evidence-Based Series 7-10 Version 2 |
| Description | Lung CT 95 IPD (PMID:7580546) CCO guideline 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Postoperative adjuvant chemotherapy with or without radiotherapy in completely resected non-small cell lung cancer. Practice guideline No 7-1-2 |
| Description | Lung CT 95 IPD (PMID:7580546) CCO guideline 7-1-2 2006 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | First-line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer . Evidence-Based Series #7-10 Version 2.2010 |
| Description | Lung CT 95 IPD (PMID:7580546) CCO guideline 7-10 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Non-small cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Description | Lung CT 95 IPD (PMID:7580546) ESMO guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD is used as evidence throughout this guideline for all stages of non-small cell lung cancer (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung CT 95 IPD (PMID:7580546) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Constitute a rational basis for the ESMO Clinical Practice Guidelines in favour of adjuvant chemotherapy in the stage II-III radically resected NSCLC patient", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Prevention, Diagnosis, Therapy and Follow-up of Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) GRS/GCS guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as Grade 1A evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Recent issues in first-line treatment of advanced non-small-cell lung cancer |
| Description | Lung CT 95 IPD (PMID:7580546) IATO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Treatment of advanced non-small-cell lung cancer |
| Description | Lung CT 95 IPD (PMID:7580546) IATO guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In 1995, an individual patient data meta-analysis demonstrated a significant benefit in overall survival for the addition of platinum based chemotherapy to best supportive care (BSC) as first-line treatment of advanced NSCLC. There are no trials comparing chemotherapy versus BSC alone, but important evidence supporting the role of chemotherapy in these patients come from the individual patient data meta-analyses, demonstrating a significant benefit with chemotherapy in patients with advanced NSCLC", based on our systematic review and meta-analysis of IPD(PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have a good PS, platinum based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb |
| Description | Lung CT 95 IPD (PMID:7580546; 10796867) AIOT guideline Stage IIIb 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546; PMID: 10796867) |
| Guideline Title | Management of Unresected Stage III Non-Small Cell Lung Cancer: Practice Guideline No 7-3 |
| Description | Lung CT 95 IPD (PMID:7580546; 10796867) CCO guideline 7-3 2006 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546; PMID: 10796867) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Lung cancer management in limited resource settings: Guidelines for appropriate good care |
| Description | Lung CT 95 IPD (PMID:7580546; 10796867) IAEA guideline 2007 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis has shown that cisplatin-based chemotherapy results in a modest survival benefit in patients with Stage III and IV disease and good PS (WHO PS 0,1); there is a 6-8 week increase in median survival and a 10% increase in 1-year survival compared to 'best supportive care" , based on our systematic review and meta-analysis of IPD (PMID: 7580546; PMID: 10796867) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Cancer Management Guidelines. Lung (including Mesothelioma & Thymoma) |
| Description | Lung Neo CT SR (PMID: 17409927) BCCA guideline 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "This data demonstrates the benefit of chemotherapy when added to definitive surgical management", based on our systematic review and meta-analysis of summary data (PMID: 17409927) |
| URL | http://europepmc.org/abstract/MED/17409927 |
| Guideline Title | ERS/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients (surgery and chemo-radiotherapy) |
| Description | Lung Neo CT SR (PMID: 17409927) ERS/ESTS guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis was cited as evidence in this guideline (PMID: 17409927) |
| URL | http://europepmc.org/abstract/MED/17409927 |
| Guideline Title | ACR Appropriateness Criteria INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER |
| Description | Lung Neo CT SR (PMID:17409927) ACR guideline Induction/Adjuvant 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| URL | http://europepmc.org/abstract/MED/17409927 |
| Guideline Title | American College of Radiology ACR Appropriateness Criteria® INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER |
| Description | Lung Neo CT SR (PMID:17409927) ACR guideline N2 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIa |
| Description | Lung Neo CT SR (PMID:17409927) AIOT guideline Stage IIIa 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP |
| Description | Lung Neo CT SR (PMID:17409927) BHKC guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Radical Management of Patients with Lung Cancer |
| Description | Lung Neo CT SR (PMID:17409927) BTS/SCTS guideline 2010 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| URL | http://europepmc.org/abstract/MED/17409927 |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC?" |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage I 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage I NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT after operable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?" |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage II before 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) JTO 2006 |
| Guideline Title | Use of Preoperative Chemotherapy With or Without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer. Evidence-based Series #7-4 Version 2 |
| Description | Lung Neo CT SR (PMID:17409927) CCO guideline 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung Neo CT SR (PMID:17409927) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "With the present status of knowledge, neoadjuvant regimens should be platinum based and at least three cycles of chemotherapy should be administered. As in advanced NSCLC, a two-drug combination of platinum and a third-generation drug seems preferable: preoperative cisplatin-based combination chemotherapy can be considered in patients with stage IIIA-N2 disease.", based on our systematic review and meta-analysis of summary data. (PMID: 17409927) |
| URL | http://europepmc.org/abstract/MED/17409927 |
| Guideline Title | NICE guideline CG121:The diagnosis and treatment of lung cancer (update of NICE clinical guideline 24). |
| Description | Lung Neo CT SR (PMID:17409927) NICE guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with NSCLC who are suitable for surgery, do not offer neo-adjuvant chemotherapy outside a clinical trial", based on our systematic review and meta-analysis of summary data (PMID: 17409927) |
| URL | http://www.nice.org.uk/CG121 |
| Guideline Title | Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Description | Lung Neo CT SR (PMID:17636828) ACCP guideline stage III 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A 2007 Cochrane meta-analysis (for stages I-III) revealed a benefit of platinum-based neoadjuvant chemotherapy over surgery alone (HR, 0.82; 95% CI, 0.69-0.97; P=.022), corresponding to an absolute benefit t of 6% to 7% in stages IB to IIIA and 3% to 5% in IIIb. When data from a European intergroup trial was added to this meta-analysis, the statistical significance was no longer present (HR, 0.88; 95% CI, 0.76-1.01; P=.07). When this meta-analysis was restricted to only patients with stage III disease, an HR of 0.73 (95% CI, 0.51-1.07; P 5 .1) was found. Taken together, these data demonstrate that surgery as the primary therapy for preoperatively identified (or suspected) N2 involvement is inferior to approaches involving neoadjuvant treatment", based on our systematic review and meta-analysis of summary data (PMID: 17636828) |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIa |
| Description | Lung PORT IPD (PMID: 15846628 AIOT guideline Stage IIIa 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Nei pazienti affetti da NSClC allo stadio IIIa-N2 radicalmente operati, il ruolo della radioterapia post-operatoria, anche se non ancora supportato da evidenze di fase III, è un trattamento che trova larga condivisione nel mondo oncologico. le dosi impiegate non dovrebbero essere superiori ai 50 Gy erogati con frazionamento convenzionale e non in concomitanza alla chemioterapia.", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Cancer Management Guidelines. Lung (including Mesothelioma & Thymoma) |
| Description | Lung PORT IPD (PMID: 9690404) BCCA guideline 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Radical radiotherapy after surgical resection is not routinely recommended", based on our systematic review and meta-analysis of IPD (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2010. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POSTOPERATIVE ADJUVANT THERAPY IN NON-SMALL CELL LUNG CANCER |
| Description | Lung PORT IPD (PMID: 9690404; 15603857) ACR guideline PostOpAdj 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404; PMID: 15603857) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio I e II |
| Description | Lung PORT IPD (PMID: 9690404; 15846628; 15603857) AIOT guideline Stage I&II 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Nei pazienti affetti da NSCLC allo stadio I-II radicalmente operati la radioterapia post-operatoria non è raccomandata.", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628; PMID: 15603857) |
| Guideline Title | BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 04) Post-operative Adjuvant Chemotherapy for Resected NSCLC |
| Description | Lung PORT IPD (PMID:10796868) BCCA guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796868) |
| Guideline Title | SIGN 137: Management of Lung cancer |
| Description | Lung PORT IPD (PMID:10796868) SIGN 137 guideline 2014 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Postoperative radiotherapy (PORT) has been shown to reduce local recurrence in the radiotherapy arm. The PORT meta-analysis suggests an adverse effect of radiotherapy on survival with a hazard ratio of 1.21 (95% CI 1.08 to 1.34), favouring surgery; two year survival with adjuvant radiotherapy was 48% versus 50% in the surgery alone group. Patients with NSCLC who have had complete tumour resection should not receive postoperative radiotherapy, except as part of a randomised trial", based on our systematic review and meta-analysis of IPD (PMID: 10796868) |
| Guideline Title | Treatment of non-small cell lung cancer, stage I and stage II. ACCP evidence-based clinical practice guidelines (2nd edition) |
| Description | Lung PORT IPD (PMID:15603857) ACCP guideline Stage I&II 2007 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There continues to be evidence that postoperative radiotherapy is associated with a decrease in survival for patients with stage I (N0) and stage II (N1) NSCLC", based on our systematic review and meta-analysis of IPD (PMID: 15603857) |
| URL | http://europepmc.org/abstract/MED/15603857 |
| Guideline Title | Non-small cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Description | Lung PORT IPD (PMID:15603857) ESMO guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Post-operative radiotherapy is not recommended for patients with radically resected stage I and II diease and should only be considred for patients with stage III disease/mediastinal involvelment", based on our systematic review and meta-analysis of IPD (PMID: 15603857) |
| URL | http://europepmc.org/abstract/MED/15603857 |
| Guideline Title | Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Description | Lung PORT IPD (PMID:15603857) ESMO guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15603857) |
| URL | http://europepmc.org/abstract/MED/15603857 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID:15603857) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques. In patients treated with surgery, postoperative radiotherapy (PORT) is not recommended unless there are positive margins or upstaging to N2", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857) |
| Guideline Title | Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Description | Lung PORT IPD (PMID:15603857; 15846628) ACCP guideline stage III 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Meta-analyses of postoperative radiotherapy (PORT) in resected NSCLC indicated a survival detriment. Subsequent studies using meta-analyses or population-based databases showed varied results in patients found postoperatively to have N2 involvement. Although it appears that PORT might benefit some patients with N2 disease, presently, it cannot be recommended for unselected patients", , based on our systematic review and meta-analysis of IPD (PMID: 15603857, (PMID: 15846628)) |
| Guideline Title | Non-small Cell Lung Cancer - Stage III |
| Description | Lung PORT IPD (PMID:15846628) AHS guideline stage III 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The Post-Operative Radiotherapy (PORT) Meta-analysis Trialists Group (2010) found evidence that post-operative radiotherapy in patients with completely resected NSCLC had a detrimental effect on overall survival. An exploratory analysis by stage and nodal status suggested that this effect was more pronounced in earlier stage patients and those with lower nodal status. Considering the results for stage III patients by themselves, there was no clear evidence of a detrimental effect of PORT (trend across all stages p=0.004)" , based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| URL | http://europepmc.org/abstract/MED/15846628 |
| Guideline Title | SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP |
| Description | Lung PORT IPD (PMID:15846628) BHKC guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "An update of the Cochrane review on postoperative radiotherapy for completely resected NSCLC was published in 2010. Combined results of the analysis based on individual patient data shows a detrimental effect of postoperative radiotherapy on overall survival (HR 1.17; 95%CI 1.02-1.34, p=0.02). Recurrence-free survival was also adversely affected by postoperative radiotherapy but that effect was not statistically significant (HR 1.09; 95%CI 0.95-1.25). Subgroup analyses for predefined factors shows no evidence that the effect of postoperative radiotherapy is different for any group of patients defined by age, sex or histology. Results for stage III disease (for the meta-analysis defined as any T-stage with N2,3 disease) show no clear evidence for neither a detrimental nor a beneficial effect of postoperative radiotherapy. For completely resected N2 disease, HR was 0.97; 95%CI 0.81 to 1.16. No further RCTs on the use of postoperative radiotherapy in completely resected lung tumours were identified.", based ou our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is strong evidence, based on an individual patient data meta-analysis and recently updated, that the use of postoperative radiotherapy following complete resection of stage I NSCLC is detrimental, and is associated with worse survival. In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC?" |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage I after 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended. There is strong evidence, based on an individual patient data meta-analysis and recently updated, that the use of postoperative radiotherapy following complete resection of stage I NSCLC is detrimental, and is associated with worse survival. In 665 patients with stage I disease randomised to PORT or no PORT, there was an increased risk of death with a hazard ratio of 1.42 (95% C.I.: 1.16, 1.75) in patients randomised to PORT", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC?" |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage II after 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In patients who have had complete resection of stage II NSCLC, postoperative radiotherapy is not recommended", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of postoperative radiotherapy (PORT) in resected stage III NSCLC?" |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Post-operative radiation therapy in patients with pN2 disease is not recommended for routine use because of the lack of prospective randomised clinical trial data demonstrating an improvement in survival", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung PORT IPD (PMID:15846628) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15846628) |
| URL | http://europepmc.org/abstract/MED/15846628 |
| Guideline Title | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung PORT IPD (PMID:15846628) ESMO guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is no indication that postoperative radiotherapy (PORT) improves outcome in patients with completely resected N0 or N1 disease, with a meta-analysis in fact demonstrating a detrimental effect on survival in these cases". "PORT in completely resected early-stage NSCLC is therefore not recommended [I, A]", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline |
| Description | Lung PORT IPD (PMID:7580546) ASCO guideline 2007 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Postoperative thoracic radiation is not recommended for patients with completely resected stage I or II NSCLC.", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| URL | http://europepmc.org/abstract/MED/7580546 |
| Guideline Title | Treatment of non-small cell lung cancer, stage IIIA. ACCP evidence-based clinical practice guidelines (2nd edition) |
| Description | Lung PORT IPD (PMID:9690404) ACCP guideline Stage IIIA 2007 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "At present post-operative radiotherapy cannot be recommended on the basis of any proof of improved survival", based on our systematic review and meta-analysis of IPD (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | ACR Appropriateness Criteria INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER |
| Description | Lung PORT IPD (PMID:9690404) ACR guideline Induction/Adjuvant 2010 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | American College of Radiology ACR Appropriateness Criteria® INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER |
| Description | Lung PORT IPD (PMID:9690404) ACR guideline N2 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| Guideline Title | American College of Radiology ACR Appropriateness Criteria® EARLY-STAGE NON-SMALL-CELL LUNG CANCER |
| Description | Lung PORT IPD (PMID:9690404) ACR guideline early 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is no established role for adjuvant radiotherapy (RT) after standard surgical resection of early-stage disease. In 1998, the Post Operative Radiation Therapy (PORT) trials group completed a large meta-analysis involving data from 9 randomized trials and reported on pooled outcomes from patients treated with or without adjuvant RT after resection for stage I to III NSCLC. This report revealed a 24% reduction in local recurrence but an absolute increase in mortality of 7% at 2 years when using adjuvant radiation, which on subset analysis was restricted to patients with stage I or II NSCLC.", based on our systematic review and meta-analysis of IPD (PMID: 9690404) |
| Guideline Title | Prevention, Diagnosis, Therapy and Follow-up of Lung Cancer |
| Description | Lung PORT IPD (PMID:9690404) GRS/GCS guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | Lung cancer management in limited resource settings: Guidelines for appropriate good care |
| Description | Lung PORT IPD (PMID:9690404) IAEA guideline 2007 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID:9690404) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID:9690404) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | Provincial non-small cell lung cancer guidelines |
| Description | Lung PORT IPD (PMID:9690404) SCA guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| Guideline Title | Treatment of Stage I & II Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Description | Lung PORT IPD (PMID:9690404; 15603857) ACCP guideline stage I&II 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | There are multiple randomized trials of PORT, all of which were collectively analyzed in a landmark study by the PORT Meta-analysis Trialists Group published almost 15 years ago. Because of confounders, it is impractical to use each individual randomized trial for guideline development, but rather, the aggregate data presented in the meta-analysis provide a more comprehensive view. For patients with completely resected pathologic stage I NSCLC, it is recommended that postoperative radiation therapy should not be used (Grade 1A)", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857) |
| Guideline Title | Radical Management of Patients with Lung Cancer |
| Description | Lung PORT IPD (PMID:9690404; 15603857) BTS/SCTS guideline 2010 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Recommendation that postoperative radiotherapy (PORT) is not indicated after R0 complete resection and a research recommendation to conduct randomised trials looking at the effect of PORT in pN2 non-small cell lung cancer are both based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | Postoperative Adjuvant Radiation Therapy in Stage II or IIIA Completely Resected Non-Small Cell Lung Cancer Practice Guideline Report #7-1-1 |
| Description | Lung PORT IPD (PMID:9690404; 15603857) CCO guideline 7-1-1 2006 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404; PMID: 15603857) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | Postoperative Adjuvant Radiation Therapy in Stage II or IIIA Completely Resected Non-Small Cell Lung Cancer. Evidence-based Series 7-1-1 Version 2 |
| Description | Lung PORT IPD (PMID:9690404; 15603857) CCO guideline 7-1-1 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Postoperative radiation therapy is not recommended for use following complete resection of stage II non-small cell lung cancer......There is evidence from a meta-analysis of individual patient data from ten randomized controlled trials that postoperative thoracic irradiation in patients with completely resected non-small cell lung cancer significantly reduces overall survival (mortality hazard ratio, 1.18; 95% confidence interval, 1.07 to 1.31; p=0.002)", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857) |
| Guideline Title | Postoperative adjuvant chemotherapy with or without radiotherapy in completely resected non-small cell lung cancer. Practice guideline No 7-1-2 |
| Description | Lung PORT IPD (PMID:9690404; 15603857) CCO guideline 7-1-2 2006 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404; PMID: 15603857) |
| URL | http://europepmc.org/abstract/MED/9690404 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID:9690404; 15603857) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques. In patients treated with surgery, postoperative radiotherapy (PORT) is not recommended unless there are positive margins or upstaging to N2", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857) |
| Guideline Title | BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 02) Adjuvant Radical Radiotherapy Following Surgical Resection |
| Description | Lung PORT IPD (PMID:9690404; 15603857; 10796868) BCCA guideline 2013 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Post-operative adjuvant radiotherapy should not be used after complete resection of Stage I or II NSCLC, due to an increased risk of non-cancer deaths.", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 10796868; PMID: 15603857 |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb-IV |
| Description | Lung SC IPD (PMID: 18678835) AIOT guideline Stage IIIb-IV 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Nei pazienti affetti da NSCLC avanzato e PS 2 secondo la classificazione ECOG (sintomatici e costretti a letto ma per meno del 50% della giornata), la chemioterapia produce un beneficio rispetto alla sola terapia di supporto in termini di sopravvivenza globale e qualità di vita. Tali pazienti sono pertanto candidati a ricevere un trattamento chemioterapico di I linea.", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| Guideline Title | American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) ASCO guideline 2009 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Evidence supports the use of chemotherapy_ in patients with stage IV† NSCLC with ECOG/Zubrod performance status of 0, 1, and possibly 2", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| URL | http://europepmc.org/abstract/MED/18678835 |
| Guideline Title | SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP |
| Description | Lung SC IPD (PMID: 18678835) BHKC guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | The use of chemotherapy in patients with stage IV NSCLC with WHO/ECOG/Zubrod performance status (PS) of 0 or 1 and (based on clinical judgement) in some cases PS 2 is recommended. This is based on a recent metaanalysis that compared the efficacy of chemotherapy with BSC and showed a benefit to chemotherapy in reduction of risk of death and an increase in 1-year survival. The meta-analysis included 16 trials with a total of 2,714 patients; 12 trials used platinum-based regimens, and 13 reported the PS. The meta-analysis found that patients with a PS of 2 also received a benefit, although it was less than the benefit seen in patients with a PS of 0 to 1. Dutch guideline7 recommends to start chemotherapy as soon as possible based on a individual based meta-analysis of 2008 on 2714 patients showing a significant benefit of chemotherapy (HR, 0.77; 95% CI, 0.71 to 0.83; P =< 0.0001), equivalent to a relative increase in survival of 23% or an absolute improvement in survival of 9% at 12 months, increasing survival from 20% to 29%.", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2010. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| URL | http://europepmc.org/abstract/MED/18678835 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| Guideline Title | SIGN 137: Management of Lung cancer |
| Description | Lung SC IPD (PMID: 18678835) SIGN 137 guideline 2014 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Results from a meta-analysis and systematic review demonstrate the benefit of SACT [systemic anticancer therapy] for patients with advanced non-small cell lung cancer (absolute improvement in survival of 9% at 12 months versus control)", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20464750) |
| Guideline Title | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 |
| Description | Lung SC IPD (PMID:18678835) AOSCG guideline 2009 |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "1-year survival was 29% for chemotherapy and 20% for best supportive care (HR 0•77, 95% CI 0•71-0•83)", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| URL | http://europepmc.org/abstract/MED/18678835 |
| Guideline Title | ERS/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients (surgery and chemo-radiotherapy) |
| Description | Lung SC IPD (PMID:18678835) ERS/ESTS guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 18678835) |
| URL | http://europepmc.org/abstract/MED/18678835 |
| Guideline Title | Treatment of advanced non-small-cell lung cancer |
| Description | Lung SC IPD (PMID:18678835) IATO guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There are no trials comparing chemotherapy versus BSC alone, but important evidence supporting the role of chemotherapy in these patients come from the individual patient data meta-analyses, demonstrating a significant benefit with chemotherapy in patients with advanced NSCLC", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| URL | http://europepmc.org/abstract/MED/18678835 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID:18678835) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 18678835) |
| URL | http://europepmc.org/abstract/MED/18678835 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID:18678835) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| URL | http://europepmc.org/abstract/MED/18678835 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID:18678835) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| Guideline Title | American College of Radiology ACR Appropriateness Criteria® NONSURGICAL TREATMENT FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER: GOOD PERFORMANCE STATUS/DEFINITIVE INTENT |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) ACR guideline NonSurgGoodPS 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The NSCLC Collaborative Group discovered a significant survival advantage with concurrent chemoradiation compared with sequential treatment (hazard ratio: 0.84) with an absolute benefit of 5.7% at 3 years.The above data have provided strong support for the use of concurrent, platinum-based chemoradiation as the standard of care for unresectable stage IIIA/B NSCLC patients who have good performance status and minimal weight loss", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | Non-small Cell Lung Cancer - Stage III |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) AHS guideline Stage III 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Auperin et al. (2010) also observed a significant benefit of concurrent chemoradiotherapy (HR 0.84; p=0.004) as compared with sequential, with an absolute survival benefit of 5.7% at 3 years, increasing survival from 18.1% in the sequential arm to 23.8% in the concurrent arm.16 However, the increase in esophageal toxicity (Grade 3-4) was significant when comparing sequential with concurrent chemoradiotherapy (4% versus 18%)", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| URL | http://europepmc.org/abstract/MED/20351327 |
| Guideline Title | Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) AIOT guideline stage IIIb 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Nei pazienti affetti da nsclc allo stadio iiib il trattamento combinato chemio-radioterapico concomitante è raccomandato quando tecnicamente fattibile e in pazienti selezionati con buone condizioni generali e assenza di comorbidità.", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) BHKC guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Patients receiving concurrent chemoradiotherapy have a better survival than patients receiving sequential chemoradiotherapy but have more oesophagitis." "When patients are considered for chemoradiation, it is recommended to offer concurrent chemoradiation in preference to sequential therapy if no contra-indications are present", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC? |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2014 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. "What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC?" |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II inoperable 2012 |
| Geographic Reach | Oceania |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327) |
| Guideline Title | EORTC Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) EORTC guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence throughout this guideline (PMID: 20351327) |
| URL | http://europepmc.org/abstract/MED/20351327 |
| Guideline Title | Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concomitant chemotherapy at systemic doses results in superior outcome to sequential chemoradiotherapy", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| URL | http://europepmc.org/abstract/MED/20351327 |
| Guideline Title | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) ESMO guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Induction chemotherapy followed by radiotherapy (mostly to a dose of 60-66 Gy in 30-33 fractions in 6-7 weeks), so-called sequential chemoradiotherapy, was compared with concurrent chemoradiotherapy to the same dose in many phase III trials and in a meta-analysis. Concurrent chemotherapy and radiotherapy lead to higher 5-year survival rates at the cost of a higher rate of reversible oesophagitis" The preferred treatment of unresectable LA-NSCLC is definitive concurrent chemotherapy and radiotherapy [I, A]", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concurrent chemoradiation appears superior to sequential therapy"; "When distant metastases are not present, the panel recommends that the patient be treated with definitive concurrent chemoradiation therapy", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| URL | http://europepmc.org/abstract/MED/20351327 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concurrent chemoradiation appears superior to sequential therapy"; "When distant metastases are not present, the panel recommends that the patient be treated with definitive concurrent chemoradiation therapy", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| URL | http://europepmc.org/abstract/MED/20351327 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy" , based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | SEOM Clinical Guidelines for the Treatment of Non-small-cell Lung Cancer: An Updated Edition |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) SEOM guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concomitant chemoradiotherapy was shown to be superior to the induction chemotherapy approach", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| URL | http://www.ingentaconnect.com/content/klu/12094/2010/00000012/00000011/00000588?crawler=true |
| Guideline Title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013 |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) SEOM guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In patients with good performance status and without significant weight loss, concurrent chemoradiotherapy at systemic doses is superior to sequential radiochemotherapy, but at the cost of manageable increased acute esophageal toxicity", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | SIGN 137: Management of Lung cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) SIGN 137 guideline 2014 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concurrent chemoradiotherapy should be administered to patients with locally advanced NSCLC (suitable for radical radiotherapy) who have a good performance status (PS 0-1)." "In patients with locally advanced NSCLC, concurrent SACT and radiotherapy confers a significant survival benefit over sequential treatment (HR 0.84, 95% CI, 0.74 to 0.95; p=0.004; absolute survival benefit 4.5% at five years) or radiotherapy alone", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | Clinical Practice Guideline: GI-009: Esophageal Cancer |
| Description | Oesophagus RT IPD (PMID:10796823) AHS guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796823) |
| URL | http://europepmc.org/abstract/MED/10796823 |
| Guideline Title | Clinical Practice Guidelines Upper Gastrointestinal Cancer - update |
| Description | Oesophagus RT IPD (PMID:10796823) BHKC guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Preoperative radiotherapy is not associated with an improved survival compared to surgery alone in patients with operable oesophageal cancer", based on our systematic review and meta-analysis of IPD (PMID: 10796823) |
| URL | http://europepmc.org/abstract/MED/10796823 |
| Guideline Title | Guidelines for the management of oesophageal and gastric cancer |
| Description | Oesophagus RT IPD (PMID:10796823) BSG guideline 2011 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Preoperative radiotherapy is not recommended for potentially resectable oesophageal squamous cell or adenocarcinoma", based on our systematic review and meta-analysis of IPD (PMID: 10796823) |
| URL | http://europepmc.org/abstract/MED/10796823 |
| Guideline Title | Preoperative or Postoperative Therapy for Resectable Esophageal Cancer. Evidence-based Series 2-11 Version 3 |
| Description | Oesophagus RT IPD (PMID:10796823) CCO guideline 2008 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796823) |
| Guideline Title | Preoperative or Postoperative Therapy for Resectable Esophageal Cancer |
| Description | Oesophagus RT IPD (PMID:10796823) CCO guideline 2012 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A Cochrane review with meta-analysis published in 2005 using updated individual patient data on 1147 patients from five trials reported ahazard ratio for death of 0.89 (95% CI, 0.78 to 1.01; p=0.062) for preoperative radiotherapy compared with surgery alone using a fixed effects model", based on our systematic review and meta-analysis of IPD (PMID: 10796823) |
| Guideline Title | Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Oesophagus RT IPD (PMID:10796823) ESMO guideline 2010 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Preoperative (with and without postoperative) radiation does not add any survival benefit to surgery alone. This treatment is not recommended [I, A].", based on our systematic review and meta-analysis of IPD (PMID: 10796823) |
| URL | http://europepmc.org/abstract/MED/10796823 |
| Guideline Title | Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Oesophagus RT IPD (PMID:10796823) ESMO guideline 2013 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Preoperative or post-operative radiation alone (without chemotherapy) does not add any survival benefit to surgery alone [9]. This treatment is not recommended for curative intent in localised tumours [I, A]", based on our systematic review and meta-analysis of IPD (PMID: 10796823) |
| Guideline Title | Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy |
| Description | Oesophagus RT IPD (PMID:10796823) GASTSG guideline 2011 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796823) |
| URL | http://europepmc.org/abstract/MED/10796823 |
| Guideline Title | SIGN87 Management of oesophageal and gastric cancer. A national clinical guideline |
| Description | Oesophagus RT IPD (PMID:10796823) SIGN guideline 2006 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Pre-operative radiotherapy is not recommended for patients with oesophageal cancer", based on our systematic review and meta-analysis of IPD (PMID: 10796823) |
| URL | http://www.sign.ac.uk/pdf/sign87.pdf |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2010 Esophageal Cancer |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The panel recommends that RT alone should generally be reserved for palliation or for patients who are medically unable to receive chemotherapy", based in part on our systematic review and meta-analysis of IPD (PMID: 9635705) |
| URL | http://europepmc.org/abstract/MED/9635705 |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2011 Esophageal Cancer. |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9635705) |
| URL | http://europepmc.org/abstract/MED/9635705 |
| Guideline Title | NCCN Guidelines Version 2.2012 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative radiation", based on our systematic review and meta-analysis of IPD. (PMID: 9635705) |
| URL | http://europepmc.org/abstract/MED/9635705 |
| Guideline Title | NCCN Guidelines Version 2.2013 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative radiation", based on our systematic review and meta-analysis of IPD. (PMID: 9635705) |
| Guideline Title | NCCN Guidelines Version 2.2014 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In the adjuvant setting, randomized trials have not shown a survival advantage for preoperative or postoperative RT alone. A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative RT", based on our systematic review and meta-analysis of IPD. (PMID: 9635705) |
| Guideline Title | Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection |
| Description | Paediatric HIV ART SR (PMID: 22786492) HHS/OARAC guideline Paediatric HIV 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The Cochrane Collaboration recently published a review on the effectiveness of cART in HIV-infected children aged <2 years based on data from published randomized trials of early versus deferred cART. The authors concluded that immediate therapy reduces morbidity and mortality and may improve neurologic outcome, but that data supporting universal initiation of treatment between ages 1 and 2 years are less compelling", based on our systematic review and meta-analysis of summary data (PMID: 22786492) |
| Guideline Title | The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary |
| Description | Pre-eclampsia PARIS IPD (PMID:17512048) CCS guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 17512048) |
| URL | http://europepmc.org/abstract/MED/17512048 |
| Guideline Title | CG107 Hypertension in pregnancy: the management of hypertensive disorders during pregnancy |
| Description | Pre-eclampsia PARIS IPD (PMID:17512048) NICE/RCOG joint guideline 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis of individual-patient data [EL = 1++] that included women with chronic hypertension showed antiplatelet agents to be effective in reducing the risk of developing preeclampsia (RR 0.90; 95% CI 0.84 to 0.97)", based on our systematic review and meta-analysis of IPD (PMID: 17512048) |
| URL | http://www.nice.org.uk/CG107 |
| Guideline Title | CG107 Hypertension in pregnancy: the management of hypertensive disorders during pregnancy |
| Description | Pre-eclampsia PARIS IPD (PMID:17512048) NICE/RCOG joint guideline 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis of individual-patient data [EL = 1++] that included women with chronic hypertension showed antiplatelet agents to be effective in reducing the risk of developing preeclampsia (RR 0.90; 95% CI 0.84 to 0.97)", based on our systematic review and meta-analysis of IPD (PMID: 17512048) |
| URL | http://www.nice.org.uk/CG107 |
| Guideline Title | EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia |
| Description | Prion SR (PMID:18391159) ENFS/ENS guideline 2012 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | No specific treatment for prion diseases can be recommended at the present time, based on our systematic review (PMID: 18391159) |
| URL | http://europepmc.org/abstract/MED/18391159 |
| Description | Regular Cochrane workshops and handbook chapter on meta-analyses of individual patient data |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2010 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID: 9400508) NCCN guideline SoftTissueSarcoma 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | Improving outcomes for people with sarcoma |
| Description | Sarcoma CT IPD (PMID: 9400508) NICE guideline 2006 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2012. Uterine Neoplasms |
| Description | Sarcoma CT IPD (PMID:10796873) NCCN UterineNeoplasms 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Doxorubicin is an active single agent for LMS and is less toxic than combination regimens", based on our systematic review and meta-analysis of IPD (PMID: 10796873) |
| URL | http://europepmc.org/abstract/MED/10796873 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2009 Uterine Neoplasms |
| Description | Sarcoma CT IPD (PMID:10796873) NCCN guideline UterineNeoplasms 2009 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796873) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2011. Uterine Neoplasms |
| Description | Sarcoma CT IPD (PMID:10796873) NCCN guideline UterineNeoplasms 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Doxorubicin is an active single agent for LMS and is less toxic than combination regimens", based on our systematic review and meta-analysis of IPD (PMID: 10796873) |
| URL | http://europepmc.org/abstract/MED/10796873 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2013 Uterine Neoplasms |
| Description | Sarcoma CT IPD (PMID:10796873) NCCN guideline UterineNeoplasms 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Doxorubicin is an active single agent for LMS and is less toxic than combination regimens" , based on our systematic review and meta-analysis of IPD (PMID: 10796873) |
| Guideline Title | Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults: Practice Guideline Report 11-2 |
| Description | Sarcoma CT IPD (PMID:9400508) CCO guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Description | Sarcoma CT IPD (PMID:9400508) ESMO guideline 2008 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Adjuvant chemotherapy is not standard treatment in adult-type soft tissue sarcomas and can be proposed as an option in the high risk individual patient", based on our systematic review and meta-analysis of IPD (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up |
| Description | Sarcoma CT IPD (PMID:9400508) ESMO guideline 2009 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2014 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN Soft Tissue Sarcoma 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy", based on our systematic review and meta-analysis of IPD (PMID: 9400508) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2012 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTisseSarcoma 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localised, resectable STS of the extremity and was associated with decreased recurrence rates", based on our systematic review and meta-analysis of IPD (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2009 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTissueSarcoma 2009 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2011 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTissueSarcoma 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Doxorubicin-based chemotherapy prolongs relapse-free survival (RFS) in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates.", based on our systematic review and meta-analysis of IPD (PMID: 9400508) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2013 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTissueSarcoma 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9400508) |
| Guideline Title | Guidelines for the Management of Soft Tissue Sarcomas |
| Description | Sarcoma CT IPD (PMID:9400508; 10796873) BSG guideline 2010 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508, PMID: 10796873) |
| URL | http://europepmc.org/abstract/MED/9400508 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2010 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID: 7640234) NCCN guideline SoftTissueSarcoma 2010 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis was cited as evidence in this guideline (PMID: 7640234) |
| URL | http://europepmc.org/abstract/MED/7640234 |
| Guideline Title | Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults: Practice Guideline Report 11-2 |
| Description | Sarcoma CT SR (PMID:7640234) CCO guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234) |
| URL | http://europepmc.org/abstract/MED/7640234 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2014 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN Soft Tissue Sarcoma 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2011 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline SoftTissueSarcoma 2011 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Available evidence suggests that anthracycline-based postoperative chemotherapy would improve DFS in selected patients who are at high risk of recurrence but otherwise are in good performance status.", based on our systematic review and meta-analysis of summary data (PMID: 7640234) |
| URL | http://europepmc.org/abstract/MED/7640234 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2012 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline SoftTissueSarcoma 2012 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Evidence from meta-analyses suggest that post-operative chemotherapy improves relapse-free survival in patients with STS of extremities", based on our systematic review and meta-analysis of summary data (PMID: 7640234) |
| URL | http://europepmc.org/abstract/MED/7640234 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2013 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline SoftTissueSarcoma 2013 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234) |
| Description | Systematic review training for Oncologists (MSc) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Guideline Title | AAWC Venous Ulcer Guidelines |
| Description | VenousUlcers IPD (PMID:19376798) AAWC guideline 2011 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19376798) |
| URL | http://europepmc.org/abstract/MED/19376798 |
| Guideline Title | AAWC Venous Ulcer Guidelines |
| Description | VenousUlcers IPD (PMID:19376798) AAWC guideline 2014 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19376798) |
| Guideline Title | Australian and New Zealand clinical practice guideline for prevention and management of venous leg ulcers |
| Description | VenousUlcers IPD (PMID:19376798) AWMA/NZWCS guideline 2011 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is minimal evidence to suggest that there is a superior compression system to prevent recurrence of VLUs.118,142 Moderate- and low -quality RCTs suggest that medical-grade compression hosiery may be more effective than compression bandages in preventing ulcer recurrence (24% vs 53%, p<0.05).", based on our systematic review and meta-analysis of IPD (PMID: 19376798) |
| Guideline Title | SIGN120. Management of chronic venous leg ulcers |
| Description | VenousUlcers IPD (PMID:19376798) SIGN guideline 2010 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis of RCTs with pooling of individual patient data from five trials comparing 4LB with short stretch bandage found that the 4LB was associated with a significantly shorter time to healing", based on our systematic review and meta-analysis of IPD (PMID: 19376798) |
| URL | http://www.sign.ac.uk/guidelines/fulltext/120/recommendations.html |
| Description | Cochrane Collaboration Methodological Improvement Project |
| Amount | £9,500 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC Hubs for Trial Methodology Research (HTMR) |
| Amount | £1,900,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2006 |
| End | 08/2013 |
| Description | MRC Population Health Sciences Research Network (PHSRN) cross Unit Appointment with MRC GPRF |
| Amount | £160,500 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | NCC RCD Research Scientist in Evidence Synthesis Awards 2004 |
| Amount | £174,517 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | NIHR No specific scheme/Prion1 |
| Amount | £8,600 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Title | Practical methods for estimation of HRs from publications |
| Description | The hazard ratio is the best statistic to use in meta-analyses of time to event outcomes. However, when hazard ratios are not reported in trial publications the methods for estimating and including tem in meta-analylses can be difficult for non-statisticians to use. We have presented a simplified guide to these methods in workshops and in an an open-access paper that includes a downloadable spreadsheet to facilitate doing the calculations (PMID: 17555582). |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2006 |
| Provided To Others? | Yes |
| Impact | Made it easier for systematic reviewers to do meta-analyses of time-to-event outcomes (such as time to death in cancer), which will ulitmately improve their quality and reliability. |
| URL | http://europepmc.org/abstract/MED/17555582 |
| Title | SCHARP software for the plotting and analysis of IPD |
| Description | The major statistical packages have been geared to the meta-analysis of aggregate data. None specifically support both the direct manipulation and analyses of and not individual patient data (IPD), but the sue of IPD is increasing. We re-developed our in-house software (SCHARP) to analyse and plot the results of IPD meta-analysis of all outcome types, and provided it to other research groups. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2008 |
| Provided To Others? | Yes |
| Impact | Made it easier for systematic reviewers to analyse and plot the results of IPD meta-analyses. As per the licence agreement (by MRC Technology), research organisations using SCHARP for published analyses must acknolwedge the Clinical Trials Unit and MRC in their publications. |
| Description | A review of RCTs in recurrent ovarian cancer |
| Organisation | University College London Hospital |
| Department | University College London Hospitals Charity (UCLH) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Carried out searches for trials, reviewed the results, and begin to develop an protocol. |
| Collaborator Contribution | Reviewed results of searches and early stage protocol developement |
| Impact | Project initiated |
| Start Year | 2014 |
| Description | Acupuncture for pregnancy outcomes during IVF |
| Organisation | Beijing University of Chinese Medicine |
| Country | China |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript. |
| Collaborator Contribution | They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript. |
| Impact | 1 paper published (PMID: 23814102). Mixed clinical and scientific expertise |
| Start Year | 2008 |
| Description | Acupuncture for pregnancy outcomes during IVF |
| Organisation | Keele University |
| Department | Research Institute for Primary Care and Health Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript. |
| Collaborator Contribution | They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript. |
| Impact | 1 paper published (PMID: 23814102). Mixed clinical and scientific expertise |
| Start Year | 2008 |
| Description | Acupuncture for pregnancy outcomes during IVF |
| Organisation | Shanghai University of Traditional Chinese Medicine |
| Country | China |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript. |
| Collaborator Contribution | They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript. |
| Impact | 1 paper published (PMID: 23814102). Mixed clinical and scientific expertise |
| Start Year | 2008 |
| Description | Acupuncture for pregnancy outcomes during IVF |
| Organisation | University of Maryland |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript. |
| Collaborator Contribution | They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript. |
| Impact | 1 paper published (PMID: 23814102). Mixed clinical and scientific expertise |
| Start Year | 2008 |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | British Columbia Cancer Agency (BCCA) |
| Department | Fraser Valley Cancer Centre |
| Country | Canada |
| Sector | Public |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Circolo Hospital and Macchi Foundation |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | European Organisation for Research and Treatment of Cancer (EORTC) |
| Country | European Union (EU) |
| Sector | Charity/Non Profit |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Freeman Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Herlev Hospital |
| Country | Denmark |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Mansoura University |
| Country | Egypt |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Newcastle General Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Queen Elizabeth Hospital Birmingham |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Royal Marsden NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Royal Prince Alfred Hospital (RPAH) Sydney |
| Department | Sydney Cancer Centre |
| Country | Australia |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Saarland University |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | The Christie NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | University Duisburg-Essen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | University Hospital La Paz |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | University of Padova |
| Department | Medical School Padua |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | University of Southern California |
| Department | Keck School of Medicine |
| Country | Unknown |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Uppsala University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Adjuvant CT for bladder cancer collaborators |
| Organisation | Wake Forest University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 publication (pre-2006) and 1 Cochrane review (PMID:16625650). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | Anti-EGFR therapy for advanced colorectal cancer |
| Organisation | University of Oxford |
| Department | CRUK/MRC Oxford Institute for Radiation Oncology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team were responsible for protocol development; searching for trials; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 conference presentations and 1 paper (PMID: 22118887). Mixed clinical and scientific expertise |
| Start Year | 2009 |
| Description | Anti-EGFR therapy for advanced colorectal cancer |
| Organisation | Velindre Cancer Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team were responsible for protocol development; searching for trials; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 conference presentations and 1 paper (PMID: 22118887). Mixed clinical and scientific expertise |
| Start Year | 2009 |
| Description | Antiretroviral therapy in HIV-infected children |
| Organisation | Queen Mary University of London |
| Department | Paediatrics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; data extraction, assessing trial quality, analysis and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data and preparing the final manuscript. |
| Impact | 1 Cochrane Review (PMID: 22786492). Mixed clinical and scientific expertise. |
| Start Year | 2010 |
| Description | Antiretroviral therapy in HIV-infected children |
| Organisation | Tygerberg Children’s Hospital |
| Country | South Africa |
| Sector | Hospitals |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; data extraction, assessing trial quality, analysis and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data and preparing the final manuscript. |
| Impact | 1 Cochrane Review (PMID: 22786492). Mixed clinical and scientific expertise. |
| Start Year | 2010 |
| Description | Antiretroviral therapy in HIV-infected children |
| Organisation | University of Padova |
| Department | Department of Paediatrics |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; data extraction, assessing trial quality, analysis and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data and preparing the final manuscript. |
| Impact | 1 Cochrane Review (PMID: 22786492). Mixed clinical and scientific expertise. |
| Start Year | 2010 |
| Description | CT for endometrial cancer collaborators |
| Organisation | Churchill Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists. |
| Start Year | 2006 |
| Description | CT for endometrial cancer collaborators |
| Organisation | Leicester Royal Infirmary |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists. |
| Start Year | 2006 |
| Description | CT for endometrial cancer collaborators |
| Organisation | Liverpool Womens NHS Foundation Trust |
| Department | Liverpool Women's Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists. |
| Start Year | 2006 |
| Description | CT for endometrial cancer collaborators |
| Organisation | University Hospitals Bristol NHS Foundation Trust |
| Department | Bristol Haematology and Oncology Centre |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists. |
| Start Year | 2006 |
| Description | CT for endometrial cancer collaborators |
| Organisation | University Hospitals Coventry and Warwickshire NHS Trust |
| Department | Oncology Coventry and Warwickshire |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists. |
| Start Year | 2006 |
| Description | CT for endometrial cancer collaborators |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript. |
| Collaborator Contribution | Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists. |
| Start Year | 2006 |
| Description | Cervical cancer patient research partners |
| Organisation | TwoCan Associates |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This partnership with women who have survived cervical cancer and allowed us to obtain their perspective on the results of a UK radiotherapy audit we conducted. Members of the research team were responsible for obtaining their views drafting an editorial of their perspective. |
| Collaborator Contribution | The patient partners provided their views on the results of a UK audit of radiotherapy.. |
| Impact | 1 editorial published (PMID:20554439) and 1 paper evaluating the project published (PMID 22587912). Mixture of cervix cancer survivors, a consumer involvement specialist and scientists. |
| Description | Chemoradiation audit collaborators |
| Organisation | Academy of Medical Royal Colleges |
| Department | Royal College of Radiologists |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This UK collaboration was established to analyse and Royal College of Radiologist Audut of chemoradiotherapy for cervical cancer. Members of the research team were responsible for refining the database; managing and analysing data, and preparing the final manuscript. |
| Collaborator Contribution | Collected the audit data. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 2 conference presentations and 1 paper (PMID: 20594810). 1 other paper in preparation. Mixed clinical and scientific expertise |
| Start Year | 2008 |
| Description | Chemoradiation audit collaborators |
| Organisation | Leicester Royal Infirmary |
| Department | Department of Oncology |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This UK collaboration was established to analyse and Royal College of Radiologist Audut of chemoradiotherapy for cervical cancer. Members of the research team were responsible for refining the database; managing and analysing data, and preparing the final manuscript. |
| Collaborator Contribution | Collected the audit data. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 2 conference presentations and 1 paper (PMID: 20594810). 1 other paper in preparation. Mixed clinical and scientific expertise |
| Start Year | 2008 |
| Description | Chemoradiation audit collaborators |
| Organisation | The Christie NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This UK collaboration was established to analyse and Royal College of Radiologist Audut of chemoradiotherapy for cervical cancer. Members of the research team were responsible for refining the database; managing and analysing data, and preparing the final manuscript. |
| Collaborator Contribution | Collected the audit data. Provided advice throughout the project, helped interpret the results and helped write the manuscript. |
| Impact | 2 conference presentations and 1 paper (PMID: 20594810). 1 other paper in preparation. Mixed clinical and scientific expertise |
| Start Year | 2008 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Acylbadem Oncology and Neurological Science Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Albany Medical College |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Centro Hospitalario Pereira Rossell CHPR |
| Department | Institute of Radiology and Center for the Fight Against Cancer |
| Country | Uruguay |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Chiang Mai University |
| Country | Thailand |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Christiana Care Health System |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Cleveland Clinic |
| Department | Lerner Research Institute |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Cross Cancer Institute |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Crozer-Keystone Health System |
| Department | Delaware County Memorial Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (TCM) |
| Country | China |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Gynaecologic Oncology Group GOC |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Institute for Oncology and Radiology of Serbia |
| Country | Serbia |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | National Cancer Institute (NCI) |
| Country | United States |
| Sector | Public |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Oncology Institute of Vojvodina |
| Country | Serbia |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Sanjay Gandhi Post Graduate Institute of Medical Sciences |
| Country | India |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Sunnybrook Health Sciences Centre |
| Department | The Odette Cancer Centre |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Tata Memorial Hospital |
| Country | India |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | University Medical Center Gronigen |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | University of Arizona |
| Department | University of Arizona Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | University of Texas |
| Department | M. D. Anderson Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | University of Yamanashi |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Vejle Hospital |
| Country | Denmark |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration |
| Organisation | Yale University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer |
| Organisation | Brussels Saint-Luc University Hospital (UCL) |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development. |
| Impact | Protocol currently being drafted, preliminary searches completed |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer |
| Organisation | Cardiff University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development. |
| Impact | Protocol currently being drafted, preliminary searches completed |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer |
| Organisation | Dana-Farber Cancer Institute |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development. |
| Impact | Protocol currently being drafted, preliminary searches completed |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Multiple |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development. |
| Impact | Protocol currently being drafted, preliminary searches completed |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer |
| Organisation | The Christie NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development. |
| Impact | Protocol currently being drafted, preliminary searches completed |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer |
| Organisation | Brussels Saint-Luc University Hospital (UCL) |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development |
| Impact | Protocol currently being drafted, preliminary searches completed. |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer |
| Organisation | Cardiff University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development |
| Impact | Protocol currently being drafted, preliminary searches completed. |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer |
| Organisation | Dana-Farber Cancer Institute |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development |
| Impact | Protocol currently being drafted, preliminary searches completed. |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Multiple |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development |
| Impact | Protocol currently being drafted, preliminary searches completed. |
| Start Year | 2014 |
| Description | IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer |
| Organisation | The Christie NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials. |
| Collaborator Contribution | Provided advice and helped with protocol development |
| Impact | Protocol currently being drafted, preliminary searches completed. |
| Start Year | 2014 |
| Description | IPD meta-analysis of adjuvant RT for prostate cancer (ARTISTIC) |
| Organisation | Auckland City Hospital |
| Country | New Zealand |
| Sector | Hospitals |
| PI Contribution | Initiated a prospective collaborative IPD meta-analysis. Published a joint letter in European Urology about the project with our trialist collaborators. |
| Collaborator Contribution | Provided information on their ongoing trials, agreed to collaborate on the meta-analysis and helped draft a joint letter published about the project |
| Impact | Published a letter to the editor of European Urology about the project |
| Start Year | 2011 |
| Description | IPD meta-analysis of adjuvant RT for prostate cancer (ARTISTIC) |
| Organisation | Dana-Farber Cancer Institute |
| Department | Department of Radiation Oncology |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Initiated a prospective collaborative IPD meta-analysis. Published a joint letter in European Urology about the project with our trialist collaborators. |
| Collaborator Contribution | Provided information on their ongoing trials, agreed to collaborate on the meta-analysis and helped draft a joint letter published about the project |
| Impact | Published a letter to the editor of European Urology about the project |
| Start Year | 2011 |
| Description | IPD meta-analysis of adjuvant RT for prostate cancer (ARTISTIC) |
| Organisation | Royal North Shore Hospital |
| Department | Northern Sydney Cancer Centre |
| Country | Australia |
| Sector | Hospitals |
| PI Contribution | Initiated a prospective collaborative IPD meta-analysis. Published a joint letter in European Urology about the project with our trialist collaborators. |
| Collaborator Contribution | Provided information on their ongoing trials, agreed to collaborate on the meta-analysis and helped draft a joint letter published about the project |
| Impact | Published a letter to the editor of European Urology about the project |
| Start Year | 2011 |
| Description | IPD meta-analysis of iron and malaria, feasibility study |
| Organisation | Liverpool School of Tropical Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration aims to establish the feasibility of assessing the effect of iron supplementation in malarious areas through and IPD meta-analysis. Members of the research team helped with protocol and feasability study development. |
| Collaborator Contribution | Helped with protocol and feasability study development. |
| Impact | We prepared a draft protocol for the meta-analysis and started the feasibility study. |
| Start Year | 2011 |
| Description | IPD meta-analysis of iron and malaria, feasibility study |
| Organisation | Tel Aviv University |
| Department | Sackler Faculty of Medicine |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | This collaboration aims to establish the feasibility of assessing the effect of iron supplementation in malarious areas through and IPD meta-analysis. Members of the research team helped with protocol and feasability study development. |
| Collaborator Contribution | Helped with protocol and feasability study development. |
| Impact | We prepared a draft protocol for the meta-analysis and started the feasibility study. |
| Start Year | 2011 |
| Description | Intermediate Clinical Endpoint in Cancer of the Prostate (ICECaP) Initiative |
| Organisation | Dana-Farber Cancer Institute |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Collaborating with the ICECaP initiative to establish a repository of RCTs in non-metastatic prostate cancer with the primary aim of identifying surrogate outcomes for survival. Will lead the planned repository of RCTs in metastatic prostate cancer. |
| Collaborator Contribution | Dana-Farber are leading this initiative |
| Impact | Ongoing |
| Start Year | 2014 |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | Academic Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | American College of Radiology |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | Cancer Institute of the Loire |
| Country | France |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | Duke University Medical Centre |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | Gülhane Military Medical Academy (GATA), Turkey |
| Department | Radiation Oncology Department (GATA) Turkey |
| Country | Turkey |
| Sector | Public |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | National Kyushu Cancer Center |
| Country | Japan |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | Netherlands Cancer Institute (NKI) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | Thomas Jefferson University |
| Department | Bodine Center for Cancer Treatment |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | University of Iowa Hospitals and Clinics |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT |
| Organisation | University of Montpellier |
| Department | Graduate Institute of Clinical Research (IURC) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript |
| Collaborator Contribution | Provided trial data, helped interpret the results and commented on the manuscript |
| Impact | 1 paper publication (PMID: 20351327). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | Canadian Cancer Society |
| Department | Canadian Cancer Society Research Institute |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Multiple |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | International Academy of Environmental Sciences (IAES) |
| Country | Italy |
| Sector | Learned Society |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | Laval Hospital |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | Queen Elizabeth Hospital Birmingham |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | Royal North Shore Hospital |
| Country | Australia |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750). Mixture of different clinical disciplinces, statisticians and other scientists. |
| Start Year | 2006 |
| Description | NSCLC Meta-analyses Collaborative Group - SC |
| Organisation | SG Moscati Hospital |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s). |
| Collaborator Contribution | Provided advice throughout the project, helped interpret the results and helped write the manuscript |
| Impact | 2 presentations at international oncology conferences, 1 paper publication (P |